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2. Summary 
Background: Glioblastoma (GBM) is the most frequent and malignant brain tumour, where 
patients have a median survival of only 14,6 months after diagnosis, thus novel, effective 
therapies are required. Natural Killer (NK) cells were investigated as effectors for adoptive 
immunotherapy against GBM due to their selective cytotoxicity against tumour cells. This 
selectivity is provided by Killer Immunoglobulin-like receptors (KIRs) that recognize self-
Human Leukocyte Antigens (HLA) as their ligands, thus inhibiting their autoreactivity.  
However, tumour or stressed cells that lack some HLA ligands become potentially susceptible 
to NK cell cytotoxicity. We hypothesized that (1) purified NK cells are more effective than 
Lymphokine Activated Killer (LAKs) cells against GBM and that (2) KIR-HLA-ligand 
mismatch might determine the killing potency of NK cells against solid tumours, such as 
GBM. 
Methods: Multiparametric (13 parameters) flow cytometry was used to phenotype the 
immune cells present in the peripheral blood of (n=8) normal healthy donors and NK cells 
were purified by magnetic beads cell sorting. Furthermore NK cells were characterised in 
detail using a panel of markers, including CD56 and CD16. Standardized in vitro culture 
methods were employed to expand and activate the NK cells, as well as generate LAK cells. 
Flow cytometry based in vitro cytotoxicity assays were used to compare killing potential of 
purified, resting or activated NK cells to LAK cells derived from the same healthy donors, in 
different effector: target (E: T)  ratios against patient-derived GBM cell lines (n=3) 
maintained in stem cell medium. The GBM cells were phenotyped for the expression of stress 
ligands MICA/B, ULPB -1,-2,-3, as well as HLA-A,-B,-C; HLA-G and HLA-E. Multicolour 
flow cytometry was used to characterize the effector populations involved in each cytotoxicity 
and their expression of activating and inhibitory KIR receptors. KIR genotyping of donors 
was performed by sequence specific primers polymerase chain reaction (SSP-PCR) and HLA-
genotyping of the GBM cells was performed by sequence specific oligonucleotide 
hybridisations (SSOP) to determine the degree of KIR receptor-HLA ligand mismatch. In 
vitro cytotoxicity assays after blocking activating receptors were also performed in order to 
determine the critical receptor for the NK cells cytotoxicity. The leukaemia K562 cell line 
was used as a positive control for the cytotoxicity assays. 
Summary 
 iii 
 
Results: Resting NK cells major subpopulation was CD56
dim
CD16
+ 
while the major 
subpopulation shifted in the activated NK cells to become CD56
bright
CD16
+
.
 LAK cells’ major 
subpopulation was T cells (72±12,5%, where CD8
+
 cytotoxic T cells [CTL] comprised 
47,44±11,9% and CD4
+
 helper T [Th]) cells were 28±13%) in addition to a minor NK cell 
population (18,1±6,4%) that was predominantly CD56
bright
CD16
dim/+
. After culture, NK cells 
up-regulated activating receptors NKp46 and NKG2D that were not abundantly expressed by 
the resting NK cells under steady state. Cytotoxicity assays demonstrated donor and dose-
dependent efficacy of NK cells against GBM cells, as well as varying potency of the effector 
cells from the same donor against the different GBM cells. Activated NK cells were more 
cytotoxic than resting NK cells and LAK cells against the same GBM and at similar E: T 
ratios. KIR-HLA ligand mismatch determined the greater cytotoxic potential of resting NK 
cells compared to activated NK cells. Ligation of activating KIR2DS2 and KIR2DS4 to their 
cognate ligands was identified for the first time to our knowledge, to determine greater 
potency of activated NK cells against GBM cells. Blocking antibodies against the activating 
receptors KIR2DS2, KIR2DS4 and NKG2D abrogated the cytotoxic potency proving the 
importance of these receptor-ligand interactions in NK cytotoxicity. 
Conclusions: Activated NK cells are more potent therapeutic effectors against GBM 
compared to LAK cells. NK cells exhibit donor-dependent efficacy against different patient-
derived GBMs due to the distinct KIR -HLA ligand mismatch between resting NK cells and 
GBM cells. However, for activated NK cells the ligation of activating KIR receptors to their 
cognate HLA ligands might be more important.  
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6. Introduction 
6.1 Cancer 
The global burden of cancer is currently 12,7 million new reported cases with an estimated 
7,6 million deaths and is projected to increase to 21,4 million with associated 13,2 million 
deaths by 2030 due to population growth and aging [1]. In Europe, 51644 new brain cancer 
cases were reported in 2009 and the incidence is projected to increase to 55477 by 2020 [2]. 
In Norway, 961 tumours of the brain and central nervous system (CNS) were diagnosed in 
2009, amounting to 3,5% of all new cases [3]. The costs associated with new cancer cases in 
2009 were estimated to US$286 billion [2], making cancer a major health and economic issue 
for the society at large.  
Cancer is not a single disease but is considered a group of diseases, characterised by 
uncontrolled growth, apoptosis resistance and spread of malignant cells to distant sites. Over 
100 different cancer types have been classified. Even though defined molecular pathways may 
differ amongst the various cancer types, the same fundamental pathways are deregulated 
through dominant loss of function mutations in tumour suppressor genes, activation of gain of 
function mutations in proto-oncogenes and unlimited replicative potential through telomere 
lengthening. Six defining hallmarks comprising common biological capabilities acquired by 
most, if not all, human tumours were proposed [4, 5]. The six Hallmarks of cancer comprise 
independence of paracrine growth factors, evasion of anti-growth signals and apoptosis, 
unlimited replicative potential, ability to form new blood vessels by angiogenesis, and to 
invade surrounding tissues and metastasise. Recently, two emerging hallmarks of cancer were 
proposed, namely reprogramming of energy metabolism and evading immune destruction [4]. 
Because neither capability is yet generalized and fully validated, they are termed emerging 
hallmarks. Additionally, they proposed two new enabling hallmarks of tumour-promoting 
inflammation and genome instability and mutation [4]. These enabling hallmarks facilitate the 
acquisition of both core and emerging hallmarks. 
 6.1.1 Brain cancer 
Among all the cancers worldwide, primary brain tumours account for 2% of all the primary 
cancers [6]. Despite this low incidence compared to the other types of cancer, they remain 
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some of the most aggressive cancers with very poor prognosis. Primary brain tumours are 
classified by The World Health Organization (WHO) classification system based on their 
morphological and phenotypical similarities to the presumed cell of origin. Thus, the 
subgroup of tumours with neuroepithelium (glia) as origin cells is called gliomas. This group 
is further sub-divided based on the predominant type of cells. Astrocytomas are thought to 
arise from astrocytes and are the most frequent gliomas making up 60% of all primary brain 
tumours. The WHO classification system further grades the astrocytomas into 4 subgroups of 
increasing malignancy, depending on the presence of histological criteria such as nuclear 
atypia, anaplasia, mitotic activity, necrosis and microvascular proliferations (Table 1). 
Tumours belonging to Grade I are the most benign astrocytomas characterised by lack of all 
of the above criteria. Grades II and III may exhibit 2 or more of these criteria, respectively, 
but both grades do not show microvascular proliferations and necrosis. Grade IV is reserved 
for glioblastoma (GBM), the most malignant, and characterised by the presence of necrosis 
and or microvascular proliferations, in addition to several of the other criteria. The grading 
system has also prognostic relevance as Grade I pilocytic astrocytomas can be cured by 
surgical resection alone, while grade IV GBM has the poorest prognosis of all the tumours 
[7]. 
Table 1: WHO classification and grading system for astrocytomas.  
 WHO Grading I II III IV 
 Type of astrocytoma Pilocytic 
astrocytoma 
Diffuse 
astrocytoma 
Anaplastic 
astrocytoma 
Glioblastoma 
H
is
to
lo
g
ic
a
l 
cr
it
er
ia
 
Nuclear atypia  ● ● ● 
Infiltrative  ● ● ● 
Anaplasia   ● ● 
Mitotic activity   ● ● 
Necrosis    ● 
Microvascular 
proliferation 
   ● 
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Represents the grading of astrocytomas by WHO system classification based on the histological criteria. 
(●) Symbolizes the criteria each type of astrocytoma presents. (Table adapted from [7] and [8]) 
6.1.1.1 Glioblastoma  
6.1.1.1.1 Symptoms and diagnosis 
Symptoms of a brain tumour are characteristically non-specific neurological symptoms, such 
as early morning headaches, nausea and vomiting, visual and cognitive disturbances and or 
paresis. Epileptic seizures are perhaps the most distinguishing sign. The type of focal 
symptoms depends also on the location of the tumour and are generally the result of increased 
intracranial pressure [9, 10]. The localization of the GBM can vary within the brain and spinal 
cord but most of them are confined within the four lobes of the supratentorial compartments 
in adults [9]. 
After physical examination, neuroimaging techniques are used for accurate diagnosis and 
follow-up of patients with gliomas. The imaging techniques include magnetic resonance 
imaging (MRI) with T1-weighted spin-echo (SE) sequence with and without administration of 
contrast agent gadolinium, and T2 fluid-attenuated inversion recovery (FLAIR). Brain 
tumours are generally revealed as poorly marginalized hypo-signal on T1-weighted and 
hyper-signal on T2 weighted sequences or FLAIR. On MRI, GBM often appears as ring-
enhancing lesions, however, as this image could resemble other diseases such as metastasis or 
abscess, the definitive diagnosis requires a stereotactic needle biopsy or a craniotomy with 
tumour resection and further pathologic confirmation [9].  
6.1.1.1.2 Incidence 
Astrocytic gliomas account for 60% of the total 2% of incidence of the primary brain tumours 
[6], while Glioblastoma (GBM) accounts 60% in Europe [6] and 54% in USA [11] of all the 
astrocytic gliomas (Figure 1).  
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Figure 1: Distribution of primary brain and CNS Gliomas by histology subtypes in USA 2005-2009 
(n=90.828).  
 
Figure taken with the permission from [11]. 
 
The incidence for GBM among young people is very low as it preferentially afflicts adults 
with a peak incidence between 45 and 70 years old people and with a median age at diagnosis 
of 59 years (median for all the primary brain and CNS tumours) [10, 11]. Gliomas develop 
most frequently in males, with an incidence rate of 7,16 male and 5,06 woman per 100.000 
person [11]. 
6.1.1.1.3 Genetic alterations 
GBM is characterised by genetic instability and apoptosis resistance [12]. Genetically, GBM 
is a very heterogeneous tumour, where the cells contain a range of genetic alterations that 
produce dysfunction and alter their normal behaviour. The most frequently altered signalling 
pathways include the receptor tyrosine kinase (RTK)/rat sarcoma (RAS)/phosphatidyl inositol 
3,4,5 bisphosphate kinase (PI(3)K) signalling, p53 and retinoblastoma (RB) tumour 
suppressor genes, which are altered in 88%, 87% and 78% of the cases, respectively [13]. 
Within these pathway alterations, loss of heterozygosity (LOH) on chromosome 10 targeting 
the phosphatase and tensin homologue (PTEN) gene [13, 14] and the amplification of EGFR 
gene (oncogenic event) on chromosome 7 are the most common in the RTK/RAS/PI(3)K 
pathway (Figure 2, a). LOH of chromosome 9 deleting the cyclin-dependent kinase inhibitor 
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2A (CDKN2A) and LOH in chromosome 17 targeting TP53 are the most frequent in the p53 
pathway (Figure 2, b). LOH on chromosome 9 deleting CDKN2A or CDKN2B are the most 
common in the RB pathway (Figure 2, c) [13]. Together these genetic alterations contribute to 
the hallmarks of GBM including unregulated proliferation, apoptosis resistance, increased 
survival signalling and tumour cell migration and invasion. 
Figure 2: Frequency of the genetic alterations observed in GBM in three critical pathways. 
 
(a) RTK/RAS/PI(3)K, (b) p53 and (c) RB signalling pathway’s components and primary sequence 
alterations are represented. Red indicates activating genetic alterations. Blue indicates inactivating 
alterations. Darker colours correspond to higher percentage of alteration. The nature of the alteration and 
the percentage of tumours affected are indicated for each altered component. Percentages in the white 
boxes refer to total percentage of glioblastomas with alterations in at least one component of the pathway. 
G. Figure taken with permission from [13]. 
 
These pathways are crucial for the progression and survival of the cells, therefore, their 
disruption, modification or alteration leads to a dramatic change or dysfunction of the normal 
behaviour of the cells. 
Introduction 
 6 
 
6.1.1.1.4 Cancer stem cells and Glioma stem-like cells  
It has been proposed that several cancer types arise from distinct but minor population of cells 
amongst the heterogeneous tumour mass. This so-called cancer stem cell (CSC) population is 
highly tumourigenic and, like the normal stem cells (SC) present in the tissues of the body, is 
capable of regenerating all the cell types of the original tumour through self-renewal and 
asymmetric cell division [15, 16].  
Therefore, two hypothesis of cancer development are established. (1) The clonal evolution 
hypothesis states that almost all the cells in a tumour are capable of extensive proliferation 
and deriving new tumours (Figure 3, a). On the other hand, (2) the CSCs hypothesis points 
that only few cells of the whole heterogeneous cancer population, CSCs, have the capacity of 
sustain tumour growth (Figure 3, b) [17, 18]. The CSCs hypothesis changed the general view 
of how cancer should be treated, in that it implied that therapies should target the minor 
tumourigenic population capable of regenerating the entire tumour at recurrence. By 
implication, the traditional therapies focused on eradicating the cells of the tumour bulk may 
be targeting the wrong cells [15, 16].  
 
Figure 3: Hypothesis of heterogeneity in solid cancer tumours.  
 
(a) Clonal evolution hypothesis. Most of the heterogenic tumour cells have the ability to proliferate and 
give rise to new tumours. (b) CSCs hypothesis. Only CSCs (yellow) have the ability to proliferate and 
form new tumours. Figure taken with permission from [17]. 
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6.1.1.1.4 Glioma stem-like markers 
Based on the clinical implication of the CSC hypothesis and on the evidence of heterogeneity 
in the ability of cancer cells to self-renew and differentiate in other cancer types, such as 
leukaemia and breast cancer, the markers that define cells with CSC features were 
investigated in our GBMs.  
CD133 is a transmembrane glycoprotein whose function is yet unknown. However, since 
neural stem cells (NSCs) are characterised by the expression of CD133 and nestin, when 
Singh et al. identified a subpopulation of GBM cells that expressed CD133, these cells were 
subsequently appointed glioblastoma stem cells (GSCs) [19, 20]. They claimed that only this 
subpopulation was tumourigenic in transplantation models and could recapitulate all the 
cellular heterogeneity of the original cancer. However, this hypothesis was refuted by several 
groups that demonstrated that also CD133
-
 cells were tumourigenic [21].  
Nestin is an intermediate filament (IF) protein class IV expressed by all the cells in the brain 
during development [22]. In the adult brain, nestin is expressed by NSCs and tumour cells 
[23, 24]. Nestin protein is able to make polymers with other IF class III, such as vimentin 
[24, 25]. Nestin and vimentin IF expression has been reported to be co-expressed together 
with CD133 in GBM [26]. 
Glial fibrillary acidic protein (GFAP) is also an IF class III that is expressed upon 
differentiation of NSCs [24, 25]. All class III IF are involved in the structure and function of 
the cytoskeleton. GFAP up-regulation has been reported as a feature of reactive astrocytes, so 
it is commonly used as a marker for astrocytes [23, 27]. Nestin, vimentin and GFAP are co-
expressed by reactive astrocytes [27]. 
GT3 gangliosides, are recognized by the ganglioside monoclonal antibody, commonly known 
as A2B5. As in the case of CD133, cells containing A2B5 ligand were thought to be a GSC 
candidate. Figarella-Branger et al. demonstrated that it was not the case, but A2B5 positive 
cells are in an early differentiation state from GSC. These cells are thought to be important for 
the initiation and malignant progression of GBM [28]. 
CD15 (3-fucosyl-N-acetyl-lactosamine), also known as SSEA-1 (stage-specific embryonic 
antigen-1), is a glycoprotein that has been reported as enriched protein in cells derived from 
GSC cells but that are CD133 negative [29].  
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6.1.1.1.5 CNS: BBB blood brain barrier - immune-privileged environment - 
It is well established that the CNS is “isolated” from the peripheral circulation by the blood 
brain barrier (BBB). The BBB is a physical, anatomical barrier that is responsible for 
maintaining the particular microenvironment inside the CNS. The BBB prevents the entrance 
of certain soluble molecules and cells to the CNS.  
Anatomically, the BBB is located at the cerebral microvascular endothelium and consists of 
endothelial cells, basal lamina, extracellular matrix, pericytes and astrocytes. The lumen of 
the capillaries in the BBB are circumscribed by single endothelial cells (ECs) that lack 
transendothelial fenestrations and are adhered to each other by tight junctions and adherent 
junctions. ECs also lack the capacity for pinocytosis and these features make them 
impermeable to passively diffused substances [30]. Astrocytes support the BBB by their end-
feet together with the high-resistance tight junctions formation [31]. Pericytes have been 
reported as regulators of the BBB and integrators of endothelial and astrocyte functions [32] 
while neurons, in the brain parenchyma, provide the neurotransmitters and metabolites 
required for the function of the nervous tissue [30]. 
This barrier regulates the access of different molecules and cells depending on various 
parameters such as size, molecular weight and charge. This tight regulation allows the brain to 
have a local microenvironment with distinct conditions from the ones present in the peripheral 
blood. The brain was thus long considered an immune privileged organ due to the presence of 
the restrictive BBB, lack of lymphatic drainage and of professional antigen presenting cells 
(APCs). However, recent investigations demonstrated central memory T cells in the cerebral 
spinal fluid and myeloid cells in the meninges and choroid plexus, as well as perivascular 
macrophages and microglia with crucial APC functions [33]. This paradigm shift has 
generated enthusiasm for the potential for immunotherapy in GBM management. 
6.1.1.1.6 Current Therapy 
Without therapy, GBM patients die within 3 months, while those maximally treated with the 
current therapy have median survival of only 14.6 months and less than 5% of GBM patients 
have a median survival of 5 years [34]. The current therapy for the GBM is a combination-
therapy, which involves debulking surgery, radiotherapy and concomitant temozolomide 
chemotherapy.  
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The aim of the surgery is to extract most of the tumour bulk and to take as little as possible of 
the normal healthy brain tissue without affecting the patient´s cognitive and neurological 
function. Due to the infiltrative nature of the GBM and the importance of the function of the 
organ the tumour is in, the complete resection of the tumour cells is often impossible [9]. 
The radiotherapy is employed after the surgery to eliminate all remaining tumour cells after 
the resection. The radiotherapy is used for killing the cancer cells because of its ability to 
exert damage to the DNA of the dividing cells. The standard radiotherapy regimen for the 
GBM is a total dose of 60Gy given in 2Gy daily fractions for 6 weeks. This fractionated 
radiotherapy allows normal cells of the brain to repair their DNA, whereas tumour cells will 
accumulate more DNA lesions that will eventually lead to apoptosis [9].  
Temozolomide (TMZ) is the standard chemotherapy used as a therapy for GBM since 2005 
[35]. TMZ (Temodar, Temodal, Temcad) is an oral prodrug that converts to 3-methyl-
(triazen-1-yl) imidazole-4-carboxamide (MTIC) that has the ability to methylate guanine 
residues of the DNA sequences at the O6 position creating toxic DNA adducts leading the 
cells to apoptotic cell death [36]. TMZ is administered together with radiotherapy in order to 
induce maximal DNA damage to the tumour cells undergoing division. However, response to 
the TMZ-radiotherapy is dependent on the presence or not of the O
6
-methyl guanine DNA 
methyl transferase (MGMT), a DNA repair enzyme. MGMT normally repairs the DNA 
adducts caused by TMZ, but when its promoter is silenced by methylation, the cancer cells 
are unable to repair the DNA damage and are thus rendered sensitive to the clastogenic effects 
of the TMZ- radiotherapy treatment. MGMT is thus a prognostic as well as predictive factor 
for response to TMZ treatment in GBM patients [36]. The feature that makes TMZ suitable 
for treatment of brain cancer is its competence for crossing the BBB because of its small 
molecular weight [36-38].  
Most GBM patients experience tumour recurrence within a median of 6,9 months post 
treatment [39]. In addition, the poor overall survival of GBM patients indicates that these 
therapies are not sufficiently disrupting the key mechanisms that drive the tumour. These 
findings emphasize the need for continued search for novel and effective therapies.  
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6.1.1.1.7 Immunotherapies of glioblastoma 
Great research effort is being invested into improved diagnosis, identifying novel therapeutics 
and overall management of GBM patients. There are several treatment strategies such as 
novel adjuvant chemotherapy, small molecule targeted therapies, gene therapy, anti-
angiogenic therapies and various immunotherapy approaches under investigation [8]. 
Adoptive cell-transfer with cytotoxic T-lymphocytes and dendritic cell vaccines have been the 
most frequently evaluated cellular immunotherapies in clinical trials for GBM patients.   
6.1.1.1.7.1 Dendritic cell (DC) vaccines    
Dendritic cell (DC) vaccines consist of antigen presenting cells (APCs) pulsed with GBM 
specific antigens. They are generated ex vivo for the purpose of antigen presentation to 
autologous cytotoxic T-lymphocytes (CTLs, CD3
+
CD8
+
) in vivo. The CTLs subsequently 
attack GBM cells expressing these antigens in situ [40].  
The procedure to obtain these APCs consists of culturing bone marrow-derived DC obtained 
from peripheral mononuclear blood cells (PBMC) together with GBM antigens obtained from 
GBM’s messenger ribonucleic acid (mRNA), fixed GBM cells or isolated GBM antigens 
[41]. This co-culturing promotes the internalization of the antigen by the DC which process it 
and further present it by their Human Leukocyte Antigen (HLA), otherwise known as the 
major histocompatibility complex (MHC) class I and II (Figure 4, a) [40]. Once generated, the 
APC are administered to the patient and upon the binding of their HLA- bound antigen to T 
cells’ receptor (Figure 4, b) and the secretion of cytokines by the APC to recruit other cells, T 
cells become cytotoxic against the GBM cells. Hence, these CTLs would recognize and attack 
specifically the GBM cells expressing the particular antigens [40, 42]. 
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Figure 4: APC and CTL formation.  
 
(a) Shows the APC formation by the interaction of the DC with antigens. (B) Represents the interaction of 
the APC with T cells via MHC class I – TCR recognition and the consequent CTL formation. Figure 
taken with permission from [43]. 
 
Based on www.clinicaltrials.gov, there are 11 trials currently in progress in various phases of 
development using DC vaccines for patient with GBM.  
6.1.1.1.7.2 Adoptive cell-transfer (ACT) with cytotoxic T-lymphocytes (CTLs) 
ACT is the process where immune cells are passively infused into a new recipient host or 
organ site with the goal of transferring their immunological function and characteristics into 
the new host. 
CTLs are T cells with cytotoxic functions. Each CTL has a unique T-cell antigen receptor 
(TCR) on the surface with specificity for a singular target peptide [40, 44]. TCR recognizes 
its specific antigen presented by HLA class I on the surface of the target cells, so the binding 
of TCR to its specific HLA-antigen triggers the cytotoxic function of CTL that results in the 
lysis of the targeted cell. Moreover, activation of the CTL causes the secretion of 
inflammatory cytokines that further recruit other necessary immune cells to create an 
inflammatory environment for the subsequent immune response.    
In establishing adoptive cell transfer (ACT) strategies for GBM treatment, GBM tumour-
reactive lymphocytes (tumour-CTLs) that recognize specially tumour antigens are required 
b a 
APC 
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[44]. For this purpose, tumour-CTLs can be directly isolated from patient biopsies or T cells 
can be cultured in different conditions in order to obtain the tumour-CTLs [45].  
 
6.2 Immune cells in the peripheral blood  
6.2.1 Peripheral blood cells 
In the human blood we can distinguish different types of cells with different features and 
functions. Blood cells can be divided in two big groups of cells, red blood cells/erythrocytes 
and leukocytes or white blood cells (WBCs). Erythrocytes have the function to bring oxygen 
to the body’s tissues while the leukocytes have an immunologic function [46].  
White blood cells are composed of 3 main types of cells (1) lymphocytes, (2) monocytes and 
(3) granulocytes. Lymphocytes have the unique capability of recognizing and distinguish 
specific foreign antigens from self-antigens and mediate immune responses.  
Lymphocytes subsets are T cells, B cells and NK cells. T cells are the mediators of the 
cellular adaptive immunity and can be further divided into 3 subtypes: CTL (CD8
+
) cells 
which have cytotoxic functions against target cells, Th (CD4
+
) cells involved in immune 
responses against different pathogens and regulatory T cells (Treg, CD4
+
CD25
+
) which 
regulate the magnitude of the immune responses. B cells are the lymphocytes capable of 
producing antibodies, activate and regulate T cells. NK cells, which are explained in detail in 
section 6.6.2, are mediators of anti-viral and anti-tumour immunity [46-48].   
Monocytes so-called macrophages in tissues are able to recognize and eliminate certain 
bacterial pathogens, and are involved in the activation of T cells and are in charge of 
eliminating the debris and dead cells from the blood [47].  
Granulocytes are also divided in 3 subtypes. (1) Neutrophils, which are phagocytic cells able 
to eliminate foreign organisms, (2) basophils, whose function is still poorly understood but 
are thought to be involved in allergic inflammations and (3) eosinophils which have a role in 
the immune regulations and are also able to degranulate their granule content against foreign 
organisms [46, 47]. 
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Leukocytes account for 4-11x10
9
cells/l of blood and their number depends on the age, weight, 
health status and gender of the person they have been taken from, as well as on the method of 
numeration, e.g. whether by flow cytometry or light microscopy (Table 2) [46, 47].   
Table 2: Proportions of peripheral blood cells in blood.  
  % of cells 
Lymphocytes 
 
B cells 2-6% 
T cells 17-34% 
NK cells 2% 
Total lymphocytes 20-40% 
Monocytes 2-10% 
Granulocytes Neutrophils or PMNs 50-70% 
Eosinophils 1-5% 
Basophils 0,5-1,5% 
Total leukocytes or WBC 100% 
Table adapted from [46] and [47]. 
 
All the blood cells have a common major progenitor, haematopoietic stem cell (HSC) whose 
differentiation starts in the bone marrow. Upon HSC differentiation, multipotent progenitor 
haematopoietic stem cell (MPP) is generated and upon asymmetrical division, gives rise to the 
common lymphoid progenitor (CLP) and the common myeloid progenitor (CMP) that gives 
rise lymphoid and myeloid lineages, respectively. Lymphoid lineage provides the 
lymphocytes (T-, B- and NK cells) of the blood, while the myeloid lineage leads to 
Granulocyte-monocyte progenitor (GMP) and Megakaryocyte-erythrocyte progenitor (MEP) 
that will provide granulocytes and erythrocyte of the blood, respectively (Figure 5) [46, 47].    
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Figure 5: Hematopoietic lineage differentiation. 
 
Lineage differentiation from a common haematopoietic stem cell (HSC) to the different cell types in the 
blood. Figure taken from [49] with permission. 
 
In order to isolate all the different types of cells from the blood, the blood is centrifuged with 
Ficoll
®
, which displaces the cells according to their density. This procedure gives plasma, 
peripheral blood mononuclear cells (PBMCs) and erythrocytes in different layers. PBMCs are 
cells with round nuclei and consist of lymphocytes and monocytes.  
6.2.1.1 Lymphokine activated killer (LAK) cells 
Lymphokine activated killer cells are activated lymphocytes generated upon in vitro culture of 
PBMCs with IL-2 and IL-15 cytokines. LAKs contain variable, donor dependent numbers of 
CTLs and NK cells and have demonstrated cytotoxic capacity against cancer [50, 51]. Several 
on-going clinical trials using LAKs are registered on clinicaltrials.gov.  
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6.2.2 Natural Killer cells (NK cells)  
6.2.2.1 General characteristics 
Natural killer cells are a subset of lymphocyte cells with the principal function of detecting 
and killing viral-infected and tumour cells. NK cells are large granular lymphocytes derived 
from bone marrow precursors and have cytoplasmic granules. They represent around 2% of 
all the leukocytes in the blood (Table 2) [47, 48].  
Some of the most typical features of NK cells are that (1) they secrete cytokines, 
predominantly interferon gamma (INF-γ) and tumour necrosis factor alpha (TNF-α), (2) they 
express a repertoire of activating and inhibitory receptors (3) they lack expression of HLA-
class I ligands but (4) express killer immunoglobulin-like receptors (KIRs) that recognize 
MHC class I motifs [52]. 
 6.2.2.2 Phenotype 
NK cells are defined, like the other lymphocytes, by the expression of particular molecules on 
their surface. NK cells do not express cluster of differentiation 14 (CD14) and CD3, markers 
of granulocytes and T cells, respectively. Hence NK cells are characterized by the following 
phenotype: CD14
-
, CD3
-
, CD56
+
 and CD16
-/+
.  
CD56 and CD16 are characteristic markers for NK cells, which are variably expressed 
depending on their state of activation. In steady states approximately 90% of the NK cells 
express CD56 in low levels (CD56
dim
) and CD16 at a higher density (CD16
+
) while the other 
10% represents CD56
bright
CD16
dim/-
 [53, 54].  
CD56, also known as neural cell adhesion molecule (N-CAM) is a membrane glycoprotein of 
the Immunoglobulin (Ig) superfamily involved in cell-cell adhesive interactions. CD56 is 
expressed by neural and muscle tissues as well as NK cells [55, 56]. CD16 is a crystallisable 
fraction (Fc) gamma receptor type III (low affinity Fcγ RIII) that recognizes the Fc domain 
(constant region of antibodies) of IgG and acts as a signal-transducing molecule [57]. CD16 is 
the receptor that triggers the antibody-dependent cell-mediated cytotoxicity (ADCC, detailed 
in chapter 1.1.1.4.2) and is also expressed by neutrophils and macrophages [58]. The 
crosslinking of CD16 with its ligand entail CD16 interaction with FcεRIγ or CD3ζ adaptor 
Introduction 
 16 
 
protein, which have Immunoreceptor tyrosine-based activating motifs (ITAM) and upon 
phosphorylation, triggers the signal cascade for the natural cytotoxicity [59]. 
In steady states, NK cells expressing CD56
dim
 contain more cytolytic granules and higher 
amount of their content and present more cytotoxic activity while CD56
bright
 are less cytotoxic 
but have been reported as the most efficient cytokine producers [53, 54]. NK cells expressing 
CD16 are therefore, more efficient in ADCC.
 
 
6.2.2.3 NK cells receptors 
NK cells express a variable repertoire of receptors on their surface. Activating and inhibitory 
receptors are both represented on the NK cells’ surface. NKG2D, NKp46, CD94/NKG2A and 
KIRs are the most characteristic and representative of them. 
NKG2D (Natural killer group 2, member D) or CD314 is an disulphide-linked type II 
transmembrane homodimeric receptor [60] that recognizes molecules highly expressed by 
transformed or virus-infected cells such as MHC class-I-chain-related protein A (MIC-A), 
MIC-B and UL16-binding proteins (ULBPs, Figure 6) [61-63]. Upon ligation of NKG2D to 
its ligands, NKG2D interacts with DAP-10, which recruits PI(3)K and triggers activating 
signals transmission downstream that leads to NK cell activation [59]. (Appendix I, Table 13). 
NKp46 (Natural killer cell p46-related protein), also known as NCR1 (Natural cytotoxicity 
triggering receptor 1) is a disulphide-linked homodimer that can associate FcεRIγ and CD3ζ 
in homo and heterodimer construction adaptor proteins (Figure 6). The crosslinking of NKp46 
with its ligand entail NKp46 interaction with its adaptor protein triggers the signal cascade for 
the natural cytotoxicity in a similar way as CD16 [59, 64, 65]. The ligands for NKp46 are at 
present not known, however, experiments blocking NKp46 with antibodies abrogates NK cell 
cytotoxicity against target cells [66], indicating indirectly that ligation of NKp46 to its 
cognate ligands triggers NK cell cytotoxicity (Appendix I, Table 13).  
CD94/NKG2s are receptors of the C-type lectin superfamily that recognize the non-classical 
HLA-E molecules and upon its recognition generate the corresponding signal cascade [67]. 
CD94 makes disulfide-bonded heterodimers with the NKG2 glycoproteins family members 
(NKG2-A, -C, -E) and seems to have chaperone function that transports the NKG2 proteins to 
the membrane (Figure 6, Appendix I Table 13) [67, 68]. NKG2A have 2 Immunoreceptor 
tyrosine-based inhibitory motifs (ITIM) that confer the inhibitory function. Upon recognition 
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of HLA-E, NKG2A associates with Src homology containing tyrosine phosphatase (SHP) 
triggering a cascade of inhibitory signalling [69]. 
Figure 6: Schematic of some NK cell receptors and their cognate ligands expressed on the target cells.  
 
 
Schematic of a NK cell (left) illustrating some of the receptors typically present on the cell surface. 
Schematic of a target cell (right), (e.g. tumour cell) illustrating the cognate ligands for the NK cell 
receptors represented on the membrane. Figure taken with permission and adapted from [70].  
6.2.2.3.1 KIR receptors  
KIRs (Killer immunoglobulin-like receptors) are monomeric glycoproteins of the Ig 
superfamily that recognize HLA class I and are expressed by NK and a small portion of T 
cells. KIRs recognize groups of HLA class I molecules that are determined by the particular 
amino acids at the c-terminal portion of the HLA class I α1 helix. KIRs are extremely 
polymorphic in terms of gene numbers, alleles present and differ in affinities for their HLA 
class I ligands [68, 71, 72].  
KIRs are divided in two subfamilies: KIR2D, which have 2 Ig-like domains and KIR3D with 
3 Ig-like domains [68]. KIRs can also be classified as activating or inhibitory, depending on 
whether they induce activating or inhibitory signals to the cell upon ligation to their HLA 
ligand. Inhibitory KIRs present long cytoplasmic domains (KIR2DL or KIR3DL) with 2 
ITIM sequences. Upon crosslinking KIR-ligand ITIMs autophosphorylate and recruit Src 
NK cells Target cells 
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homology containing tyrosine phosphatase (SHP-1 and -2) adapter proteins. SHP upon 
binding Vav-1 triggers inhibitory signal cascade [62, 69]. 
The activating KIRs are characterized by short cytoplasmic domains (KIR2DS or KIR3DS) 
with no ITIM motifs but with a charged amino acid in the transmembrane domain [68]. 
Activating KIRs interact with DAP12 protein, which contains ITAM. Upon the crosslinking 
of activating KIR to DAP12, DAP12 is autophosphorylated and binds ZAP-70 or Syk tyrosine 
kinases (TK), therefore, a cascade of activation of proteins downstream is initiated with the 
purpose of activating the NK cell for the target cell killing [59, 73].  
Both activating and inhibitory signals that NK cells receive from its receptors are 
implemented to the common pathway of GTPase-activating protein 1 (Rac)/mitogen-activated 
protein kinase (MAPK)/extracellular signal-regulated kinase (ERK)/p21-activated kinase 
(PAK)/ mitogen-activated or extracellular signal-regulated protein kinase (MEK) [62].  
KIR2DL1 and KIR2DS1 recognise HLA-C with a Lys80 residue (HLA-C group 2 specificity) 
whereas KIR2DL2 and KIR2DL3 allelic forms recognize the HLA-C1 group with Asn80 
residues [74]. However, others have demonstrated interaction between KIR2DL2 and 
KIR2DL3 with HLA-C2 allotypes [75]. Inhibitory KIR3DL1 interacts with Bw4-containing 
HLA-B alleles and KIR3DL2 recognises HLA-A3 and HLA-A11 allotypes [71] (Figure 6, 
Appendix I, Table 13).  
Concerning the KIR activating receptors, although KIR2DS2 was first thought to bind the 
same HLA-C as KIR2DL2, Eric Vivier et al. refuted this hypothesis [76], therefore KIR2DS2 
ligands remain unknown. KIR2DS4 activating KIR recognizes Cw4-containing HLA-C [77] 
(Figure 6, Appendix I, Table 8). 
6.2.2.3.2 NK cell activation and “Missing-self” hypothesis 
NK cells recognise and kill tumour or virus infected cells lacking class I- HLA ligands 
recognised by KIRs (6), through the “missing-self” hypothesis (7) or KIR-HLA mismatch.  
NK cells are capable of distinguishing self from non-self-cells due to the interaction between 
their KIR receptors and their corresponding ligands on the target cell. The NK cells of our 
body interact by their KIR with the HLA class I molecules that all our body cells express on 
their surface. The interaction of inhibitory KIR to their cognate -HLA ligands transmits 
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inhibitory signals to the NK cell meaning “this is a self-cell, don’t kill it”. When the NK cells 
interact with a cancer or virus infected cell, which express differently HLA class I molecules 
than the healthy self-cells (either by not expressing HLA ligands for the KIR receptors or 
express different HLA allele repertoire than the self-cells), the KIRs do not interact with them 
so the inhibitory signal is not sent to the cell, meaning “this is not a self-cell because it has 
missing self-markers”. This lack of the inhibitory signal together with the activating signals 
the cell may receive activates NK cell and licences it to kill the target cell (Figure 7, b) [69, 
78-80]. 
As mentioned above, NK cells also interact with the target cells by their activating receptors. 
The activating receptors (such as NKG2D and NKp46) recognize stress ligands and send 
activating signals to the NK cell. When NK cells interact with a target cell, they receive both 
activating and inhibitory signals. Thus the overall balance between activating and inhibitory 
signals determines whether the NK cell will remain anergic or become cytotoxic.  
 Figure 7: Tolerance, missing-self or mismatch hypothesis and stress-induced self.  
 
(a) When the balance between inhibitory and 
activating receptor-ligand is positive for the 
inhibitory KIR-HLA interactions, inhibitory 
signals are sent to the NK cell, so the target cell is 
not killed by the NK cell. This is the typical 
situation for the healthy self-cells, and is also 
known as tolerance. 
 
(b) If the balance between inhibitory and activating 
receptor-ligand is positive for the activating 
receptor-ligand interactions, this interaction will 
send activating signals to the NK cell and the target 
cell will be killed. This is the case of the tumour and 
virus-infected cells and is called “Missing self”. 
 
(c) In the case that both activating and inhibitory 
receptors have bound its ligand but the activating 
receptors have bound large amount of stress 
ligands, the balance turns to positive for the 
activating signal. This is called stress-induced self 
because even though the cells recognize self HLA 
molecules and send inhibitory signal, strong 
activating signal is also received indicating that 
something is wrong with the target cell. This is the 
situation for the tumour cells. 
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KIRs are highly polymorphic, in terms of gene numbers and alleles, and due to the variability 
of affinities for their HLA class I ligands [71, 81]. The fact that NK receptors and their HLA 
class I ligands are not genetically linked, in some situations, a receptor for self-HLA class I 
ligand might not be expressed by autologous NK cells. This fact enhances complexity to the 
KIR-HLA ligand recognition [82].  
6.2.2.4 Cytotoxicity function 
NK cells kill their target cells by secreting the contents of the cytotoxic lysosomes in a 
response of two situations; (1) positive balance in the activating/inhibitory signal obtained by 
the surface receptors (Lysosomes secretion cytotoxicity, Figure 8 and chapter 6.2.2.4.1) and 
(2) recognition of the specific antibodies that bind the antigen of their target cells (antibody-
dependent cell-mediated cytotoxicity, Figure 8 and chapter 6.2.2.4.2). These processes are 
summarised in the schematic below. 
Figure 8: Cytotoxic functions of NK cells against tumour cells. 
 
[83] 
6.2.2.4.1 Lysosomes secretion cytotoxicity  
NK cells contain lysosome organelles in the cytoplasm, in which various enzymes and 
proteases are contained, they make them be capable of an immediate non-antigen specific 
response, without transcription, translation or cell proliferation requirements [69, 84]. Upon 
receiving activating signals from their surface receptor-ligands interactions, NK cells release 
the contents of their lysosomes inducing the apoptosis of the target cells.  
(1) 
(1) 
(2) 
(1) Lysosomes secretion cytotoxicity. 
Granszyme B and perforin are most of 
the content of NK cells lysosomes and 
are the mediators of the tumour cell 
cytolysis. (2) Antibody-dependent cell-
mediated cytotoxicity (ADCC). Fc 
receptor (CD16) is represented 
recognizing the Ab linked to its 
antigen in the surface of the tumour 
cell.  Fas ligand (FasL) and Fas, which 
is an apoptotic receptor, are also 
represented [83].  
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NK lysosomes contain cytotoxic proteins such as perforin and granzymes (Figure 8, 1). Due 
to the lytic power of those proteins, signalling resulting in their release is very tightly 
regulated. Firstly, NK cells contact the target cells by cell-cell associations. Although little is 
known about the mechanisms of this association, studies indicate that selectin family 
members and CD2 may be involved [85]. Once the target cell is attached to the NK cells, the 
latter receives initial intracellular activating signalling and an activated-lytic synapse is 
formed at the connection point. Integrin family adhesion molecules such as lymphocyte 
function associated antigen-1 (LFA-1) and macrophage-antigen-1 (MAC-1) have been shown 
as mediators of stronger adhesion in the synapse formation. Further activating signalling 
attends this adhesion, rearrangements of actin cytoskeleton take place and MTOC 
(microtubule-organizing center) and lysosomes lead to the synapse point [86]. Lysosome must 
fuse with the membrane of the target cell membrane to be able to release their content on the 
NK-target cell interface and SNARE (N-ethylmaleimide-sensitive factor) or equivalent 
protein may be involved in that membrane fusion-procedure [85]. Unfortunately, there is no 
conclusive evidence yet of that protein’s interaction on NK cell lysosomes secretion and 
subsequent cytotoxicity [85]. 
NK lysosomes contain two different types of proteins: pore-forming proteins and proteases. 
Perforin belongs to the first group and polymerizes and inserts itself into the target cell 
membrane making a pore by creating transmembrane tubules. This pore made by the perforin 
partly disturbs the osmotic state of the cell and allows proteases access into the cell to mediate 
cell death. The main proteases the NK lysosomes contain are granzymes, which remain 
inactivated in the lysosomes because of the acidic pH. The major granzymes in terms of 
amount are Granzyme B and A, but Granzyme B is the most potent one. Their main function 
is to induce apoptosis of the cell [87]. Granzyme B achieves this purpose by attaching to 
caspase-3 and some of its substrates leading to DNA fragmentation and apoptosis [88].  
6.2.2.4.2 Antibody-dependent cell-mediated cytotoxicity (ADCC)  
Although ADCC is a cytotoxicity process that can be carried out by NK cells, neutrophils and 
macrophages also induce it. ADCC is a process that requires the interaction of 3 molecules, 
(1) an antigen on the target cell that is recognized by (2) an antigen-specific antibody (Ab) of 
a suitable isotype and (3) the FcR present on the cytotoxic cell. The FcR on NK cells is CD16 
(low affinity Fcγ RIII) [57]. The interaction between NK cells and the target cancer cell via 
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the Fc constant domain of the Ab and CD16 (Figure 8, 2), respectively, mediates the 
activation of the NK cell, induce its pro-inflammatory cytokines release and triggers NK cell 
cytotoxic function [89]. The releasing of INF-γ, tumour necrosis factor-α (TNF-α) and other 
chemokines potentiates the recruitment of other immune cells, thus promoting a pro-
inflammatory immune environment, the release of the lysosomal content and, ultimately, lysis 
of the target cell [84]. 
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7. Hypothesis and Aims 
The present thesis represents initial studies of the potential of allogeneic NK cells as a 
therapeutic agent against GBM before taking this investigation into in vivo experiments. 
Therefore, this project was built to achieve the following hypotheses and aims: 
 
7.1 Hypothesis  
We hypothesized that: 
1. Purified human NK cells can be successfully expanded as opposed to LAK cells 
from the same healthy donor. 
2. Purified NK cells from healthy donors can be activated in culture to be more 
cytotoxic than LAK cells against GBM cells in vitro.  
3. KIR-HLA ligand interactions may mediate NK cells’ cytotoxic potency against 
GBM cells. 
 
7.2 Aims 
1. Characterise major population of NK cells in peripheral blood of healthy donors and 
the impact of cell culture on expression of phenotypic markers.  
2. Compare purified NK and LAK cells for the ability of expansion using standard 
methodology.  
3. Investigate the cytotoxicity potency of NK cells vs. LAK cells from healthy donors 
against GBM stem like cells.  
4. Investigate the role of KIR-HLA interactions in determining cytotoxic efficacy of 
resting vs. activated NK cells.  
5. Identify the KIR-HLA ligand interactions most critical in determining NK cytotoxic 
potency against GBM. 
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8. Materials and methods 
 
8.1 Blood donors and extraction 
Eight healthy donors were enrolled into the study and gave their informed consent to their 
participation. The study was approved by the REKvest ethical board. 25-40ml of blood was 
extracted by a trained phlebotomist at the same time of the day, between the hours 10am-
14pm (Table 3). For the extraction, butterfly cannulas (green, needle gauge with adapter and 
holder Vaccuette
®
 (Ref: G450085, Greiner bio-one, Germany) were used. The blood was 
collected in Vaccuette
®
 blood collection tubes (9ml K3EDTA tubes, Ref: 455036, Greiner 
bio-one) and stored overnight at 4°C in the fridge (for less than 24h). 
Table 3: Donor demographics, time and volume blood extraction. 
Donor 
number 
Age 
(years) 
Gender Origin Volume of 
blood 
Time of extraction 
1 27 Female Polish 40ml 11-12h 
2 26 Female Iranian 25ml 13-14h 
3 26 Male Turkish 30ml 10-11h 
4 39 Male Norwegian 30ml 11-12h 
5 26 Female Polish 36ml 12-13h 
6 32 Male Estonian 36ml/27ml 10-11h/ 13-14h 
7 26 Male Spanish 36ml 12-12:30h/ 11:30h 
8 28 Male Iranian 36ml 11-12h 
 
 
8.2 GBM cell lines 
We established GBM cell lines from patients’ biopsies obtained from routine craniotomy 
surgery performed at the Neurosurgical Department at Haukeland University Hospital 
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(Bergen, Norway). The collection of biopsy material into the GBM biobank was approved by 
the REKvest regional ethical board. The GBM cells were used as target cells in the cytotoxic 
assays. P3, 2010-046, 2010-062, 2012-020, 2010-20-I and 2012-018 were established from 
GBM patients’ biopsies and the K562 cell line (ATCC, Sweden) from the chronic myeloid 
leukaemia patient. K562 cells lack MHC class 1 molecules and are highly susceptible to NK 
cell lysis [90]. Hence these cells were used as a positive control in the cytotoxic assays.  
 
8.3 Cell isolation 
8.3.1 Peripheral blood mononuclear cells (PBMCs) isolation 
PBMC isolation was performed in order to obtain immune cells from blood for subsequent 
studies, such as antigenic phenotyping, natural killer cells (NK cells) isolation and culture of 
PBMCs to obtain lymphokine activated killer cells (LAKs). PBMCs were isolated from the 
overnight-stored donor blood by using density gradient centrifugation method. Leucosep
®
 
(50ml tubes with an high density polyethylene membrane HDPE, Cat n°: 227290, Greiner 
bio-one) were used and 15ml of lymphocyte separation medium  (Cat n°: 17-829E, Lonza, 
Lysaker, Norway) was added and centrifuged for 5min at 400 rpm (Biofuge stratus, Heraeus 
instruments) at room temperature. After this, the lymphocyte medium collected below the 
membrane. Then, 20-25ml of 1:1 blood/phosphate buffered saline (PBS) was added on the 
membrane and centrifuged for 15min at 400rpm in room temperature.  
Lymphocyte separation medium is composed by a mixture of Ficoll
®
 and sodium diatrizoate 
with adjusted density to 1,077 g/ml. Ficoll
®
 is a hydrophilic polymer used to create a density 
gradient of the blood cells in the sample, after centrifugation. PBMCs are distributed in that 
gradient as a white band above the HDPE membrane (Figure 9).  
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Figure 9: Leucosep® with Lymphocyte separation medium and blood dilution after centrifugation. 
 
 
8.3.2 Natural killer (NK) cells isolation 
NK cell isolation was performed in order to obtain pure NK cells for the cytotoxicity studies. 
NK cells were isolated from the healthy donors’ PBMCs by using a negative selection 
procedure on magnetic column (NK Cell Isolation Kit, order no: 130-092-657, Miltenyi 
Biotech, Germany). 
Briefly, to eliminate of cell clumps, PBMCs, were passed through a 30 µm pre-separation 
filter (Order nº: 130-041-407, Miltenyi Biotech). Then the cells were ready to be labelled 
according to the manufactures’ protocol; Biotin-Ab cocktail, containing Biotin conjugated to 
Ab against lymphocytes but NK cells lineage-specific antigens, was added to the cells and 
incubated for 13 min. Thereafter, Microbeads Cocktail, containing beads conjugated to 
monoclonal Ab, was added and incubated 15min. After one washing with 2 ml. of MACS 
Buffer (MB) the cells were passed through the magnetic column (LS Column, Order no: 130-
042-401, Miltenyi Biotech) (Figure 10), followed by 5 times MB column washes.  
 
 
 
Plasma 
PBMC 
HDPE membrane 
Erythrocytes 
Lymphocyte separation medium   
Blood cells distributed in different layers by 
density gradient. PBMCs are the white band 
situated between the membrane and the 
plasma band. 
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Figure 10: Schematic drawing of a negative selection procedure by magnetic beads column, denoted north 
(N) and south (S). 
 
[91] 
 
8.4 Cell culturing 
8.4.1 PBMCs culturing 
In order to obtain lymphokine activated killer (LAK) cells, PBMCs were cultured after the 
isolation for one week in RPMI-1640-Glutamax medium (Sigma-Aldrich, St. Louis, Missouri, 
USA) supplemented with 10% v/v Fetal Cow Serum (FCS, Cat nº: A4503, Sigma-Aldrich), 
5% v/v Penicillin-Streptomycin antibiotics (PS, Cat nº: DE17603E, BioWhittacker Inc., 
Walkersville, Maryland, USA), 1mM Hepes with 0,85% NaCl (Cat n°: 17-829E, Lonza), 
100U/ml IL-2 (Cat nº: 202-IL-050, R&D System, UK) and 50ng/ml IL-15 (Cat nº: 247-IL-
025, R&D System). The cells were cultured in the concentration of 1x10
6
cells/ml in 12 or 6 
well-plates (Thermo Scientific Nunclon
®
, Waltham, Massachusetts, USA), depending on the 
total amount, and were incubated at 37°C and 5% of CO2 (Steri-Cycle CO2 incubator, Hepa 
Class 100, Thermo electron corporation). 0,5 ml of the same supplemented medium was 
added each 2-3 days.  
8.4.2 NK cells culturing 
In order to activate and expand the purified NK cells, they were cultured after the isolation for 
two weeks with sterile good manufacturing practice (GMP) serum free Stem Cell medium 
(A) Shows the start point with a mixture of cells (PBMCs), 
the not relevant (in black) are labeled with magnetic beads 
conjugated to monoclonal antibodies (Abs). The cells of 
interest (in white), NK cells, are not labeled. (B) Represents 
the attachment of bead-Abs labeled cells to the magnetic 
field and the collection of the isolated pure, “untouched” 
NK cells. Figure taken with permission from [91]. 
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(SC, Cat nº: 20802-0100, CellGenix, Freiburg, Germany) supplemented with 10% v/v FCS, 
500U/ml IL-2 and proliferation beads of NK Cell Activation/Expansion Kit (Cat nº: 130-094-
483, Miltenyi Biotech) according to the protocol. The activation beads consist of anti-NKp46 
and anti-CD2 antibodies conjugated to microbeads. The cells were cultured in a concentration 
of 1x10
6
cells/ml in 6 well-plates and were incubated at 37°C and 5% of CO2. 0,5 ml of the 
supplemented medium without the activation beads was added each 2-3 days and the cells 
were passaged when they became too dense.  
8.4.3 K562 culturing 
K562 is a cell line that we used as a positive control in the cytotoxicity assays. It was cultured 
in suspension with RPMI-1640-Glutamax medium supplemented with 10% v/v FCS, 5% v/v 
PS, 1mM Hepes with 0,85% NaCl. The cells were cultured at a concentration of 
0,2x10
6
cells/ml in 75 cm
2 
Nunc

 Easy flasks (with Nunclon Δ, Cat nº: 156499, Thermo 
Fischer Scientific) and incubated at 37°C and 5% of CO2. The cells were passaged when they 
became too dense and only cells in the exponential phase were used for the assays.  
8.4.4 Patient-derived GBM cells culturing 
P3, 2010-046, 2010-062, 2012-020, 2010-20-I and 2012-018 GBM cells were cultured with 
NeuroBasal

 medium (NB, Cat nº: 21103-049, Invitrogen Hämeenlinna, Finland) 
supplemented with 1% v/v GlutaMAX

 (Cat nº: 35050-061, Invitrogen), 2% v/v B-27

 
(Supplement Minus Vitamin A, Cat nº: 12587-010, Invitrogen), 5% v/v PS, 20% v/v 
recombinant human epidermal growth factor (EGF, Cat nº: AF-100-15, PeproTechc SE, 
Stockholm) and 20% v/v  recombinant human basic fibroblast growth factor (FGF, Cat nº: 
100-18B, PeproTech SE, Stockholm) to be used in cytotoxicity assays. The cells were 
cultured in 25 cm
2 
Nunc

 Easy flasks (with Nunclon Δ, Cat nº: 156367, Thermo Fischer 
Scientific) and incubated at 37°C and 5% of CO2. They were passaged when they became 
dense and only cells in the exponential phase and within passages 1-25 were used for the 
assays.  
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Table 4: GBM patient biopsies information of the GBM cells in culture.   
Patient ID Cancer type Gender Age 
P3 GBM Male 64 
2012-018 GBM Gliosarcoma Male 81 
2010-20-I GBM Male 51 
2010-046 GBM Female 61 
2010-062 GBM Male 66 
 
 
8.4.4.1 P3 and 2011-20-I 
P3 and 2011-20-I are GBM xenograft cell lines that have been serially passaged in vivo in 
nude rats (Table 4). P3 were carefully grown as monolayers in 25 cm
2 
flasks while 2011-20-I 
grown as partial suspension and monolayers. 24 mm
2
 cell scrapers (TPP Tissue Cell Scraper, 
Cat nº: 99002, MidSci, St. Louis, Missouri, USA) were used to detach the cells from the 
substratum during the passaging.  
8.4.4.2 2010-046, 2010-062, 2012-020 and 2012-018 
These are GBM primary culture lines that are derived directly from patients’ tumour material.  
2010-046 and 2010-062 GBM cells (Table 4) were grown in flasks as monolayers, while 
2012-020 cells were grown half attached half in suspension and 2012-018 cells (Table 4) were 
grown as both monolayers and spheres, both attached to the substratum. In all the four cases 
24 mm
2
 scrapers were used to detach the cells during de passaging.  
 
8.5 Cell counting 
In order to calculate the concentration of cells present in the blood samples, the cells were 
counted by using Bürker counting chamber. The Bürker chamber is a standard cell counting 
method that consists of one chamber with two rafters to add samples of cells to be counted. 
Each rafter has an engraving of nine big squares of 1 mm
2
 area encoded in 3 parallel lines 
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sides each (Figure 11, A). The chamber covered with cover slip is 0,1 mm deep. Therefore, 
each of the 9 squares has a 0,1mm
3
 of capacity.  
For our studies it was important to count only viable cells, so Trypan blue solution (0,4% in 
0,81% Sodium Chloride and 0,06% potassium phosphate, dibasic; Cat n°: 72-75-1, Sigma-
Aldrich) was used in 1:1 concentration to be able to distinguish the dead and live cells. 
Trypan blue is a dye that is not permeable to the membrane of live cells but diffuses freely 
into dead cells because of the disruption of those cells’ membrane. After Trypan blue staining 
the live cells are distinguished as round, phase bright and unstained while the dead cells 
typically have irregular shape, are phase dim and retain the trypan blue colour (Figure 11, B, 
arrow). 
To proceed to the counting 10µl of cells suspension was mixed with 10µl of Trypan blue in an 
eppendorf

 tube (0,5ml, Cat nº: 0030 121.023, Eppendorf) and 10µl aliquot of the mix was 
added to the space between the chamber and the cover slip. Cells within the 1 mm
2 
and the 
ones lying on the upper and left sides were counted using 10x objective of Microscope 
(Olympus CKX31), (Figure 11, B). It is important to point out that at least three out of nine 
squares of 1 mm
2
 area were counted to ensure accuracy. 
To calculate the number of cells present in the sample, the equation below was used, 
 
Where: 
n: number of cells in all the 1 mm
2
 counted squares. 
V: total volume of the cell suspension in millilitres. 
s: number of 1 mm
2
 area counted squares (normally s=3). 
d: dilution of the cell suspension sample due to addition of TrypanBlue (normally d=2).  
 
 
 
 
Number of cells = n*d*V*10
4
/s 
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Figure 11: Bürker chamber details. 
 
(A) Detail of the nine 1 mm
2
 area squares encoded in 3 parallel lines sides each. (B) Detail of one 1 mm
2
 
area square. Black dots represent viable cells in the right area to be counted. White dots represent cells 
which are not in the counting area because they lie on the bottom edge and the right side. The arrow 
points to a blue irregular shaped, phase dark/dim dead cells after the Trypan blue staining. Dead cells are 
excluded of the counting. Figures taken from [92, 93]. 
 
8.6 Cell staining  
In order to characterize the phenotype of the PBMCs, NK and GBM cells used in this study, 
fluorochrome conjugated (Fl-conjugated) primary Ab, Fl-conjugated secondary Ab and 
intracellular cell staining were required to detect the expression of different markers by flow 
cytometry.  
8.6.1 Fluorochrome-conjugated primary Ab staining 
Antibodies (Ab) against all the markers of interest were, conjugated to different 
fluorochromes and the majority was used to detect surface markers of the different cells 
within the sample. The cell staining was done 0,5-1x10
6
 cells in FACS tubes (5ml 12x75mm. 
Polystyrene round-bottom tubes, Ref: 352052, BD Biosciences Falcon
®
). Cells were 
incubated with the relevant Abs at previously optimised concentrations (see table?) for 20min 
at 4°C protected from light. After a couple of washing of the samples with FACS buffer (FB), 
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1 µl  Live/Dead Fixable Near-IR Dead Cell Stain Kit (L/D, Cat nº: L10119, Invitrogen) was 
added to distinguish the fluorescent signal emanating from the dead cells and the specific 
bonafide staining due to the binding of Ab-conjugated fluorochromes to the right epitopes. 
Live/Dead

 Kit contains a fluorescent dye that binds to free amines both in the surface and 
inside of the cells. Due to the compromised state of the dead cells membrane, they are stained 
both on the surface and inside the cell, thus, dead cells are brightly stained than the alive cells, 
which are only stained on the surface. Staining in the tubes was undertaken in a final volume 
of 100µl of FB (Table 4).  
Due to the lack of available specific Abs against certain molecular markers, such as KIR3DL2 
and KIR2DL2, Abs against two of the subtypes of those markers were needed to be used. 
Therefore, anti-KIR3DL2/1 along with anti-KIR3DL1 and anti-KIR2DL2/3 coupled with 
anti-KIR2DL3 were applied. In the staining tubes that contain those combined Abs, previous 
incubation of the sample with only anti-KIR3DL1or anti-KIR2DL3 Abs were required in 
order to occupy specifically their epitopes. Thus, in a second incubation with all Fl-
conjugated Abs, anti-KIR3DL2/1 or anti-KIR2DL2/3 were added to attach to the KIR3DL or 
KIR2DL left by the common Abs against two subtypes (mostly KIR3DL2 or KIR2DL2, 
respectively).  
Control and compensation samples were needed in addition to the experimental samples. 
Three control tubes were included: one with only cells and no Ab added, to determine the 
auto-fluorescence of the unstained sample; another with isotype control Abs, to be able to 
check any unspecific binding of the isotype Ab to the samples; and the third one with isotype 
control Abs and some Fl-Abs, to detect any signal interference between isotype Abs and the 
Fl-Abs. The compensation tubes were needed for calibrating the flow cytometer settings 
before acquiring and data analyzing and to determine the spectral between detection channels 
(compensation tubes use is further explained in detail in 8.9.1.3 chapter). 
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Table 5: Example of NK cells and PBMCs staining frame. 
   Sample V450 V500 BrillViol570 FITC PE PE-Cy5 PE-Cy7 APC Alexa700 APC-Cy7 
1 PBMC                     
2 PBMC  IgG1     IgG2b             
3 PBMC CD56                   
4 PBMC   CD3                 
5 PBMC     CD4               
6 PBMC       CD16             
7 PBMC         NKG2D           
8 PBMC           CD14         
9 PBMC             CD8       
10 PBMC & beads               NKp46     
11 PBMC & beads                 NKG2A   
12 PBMC                   L/D 
13 PBMC CD56 CD3 CD4 CD16  CD14 CD8  IgG2a L/D 
14 PBMC donor CD56 CD3 CD4 CD16 NKG2D CD14 CD8 NKp46 NKG2A L/D 
15 PBMC donor CD56 CD3 CD4 CD16 NKG2D CD14 CD8   NKG2A L/D 
16 NK donor CD56 CD3 CD4 CD16 NKG2D CD14 CD8 NKp46 NKG2A L/D 
17 NK donor CD56 CD3 CD4 CD16 KIR3DL2/1 CD14 CD8 KIR2DL4 KIR3DL1 L/D 
18 NK donor CD56 CD3 CD4 CD16 KIR2DL2/3 CD14 CD8 KIR2DL3 KIR2DL1 L/D 
19 non-NK CD56 CD3 CD4 CD16   CD14 CD8     L/D 
Columns represent the different channels selected for the detection of the used fluorochromes. Rows 
represent different sample tubes. Tubes 1-2 and 13 are controls and un-specificity-binding checking tubes. 
Tubes 3-12 are compensation tubes used do compensate the signal in the machine. Tubes 14-19 are the 
tubes of study. In tubes 17 and 18 KIR3DL1 and KIR2DL1, respectively, are highlighted in purple due to 
fact that they needed to be added before the whole staining.   
8.6.2 Fluorochrome-conjugated secondary Ab staining 
For the GBM cell phenotyping sequential staining with primary Abs, followed by secondary 
Fl-conjugated was required. The secondary Ab staining was done as a second step to the full 
primary Ab staining. 0,5-1x10
6
 cells were placed in FACS tubes after couple of washing steps 
with FB. The primary Ab was added in a final volume of 100µl of FB and incubated for 
20min at 4°C protected from light. This incubation was followed by a washing step and 
incubation with the secondary Ab under the same conditions as with the primary Ab. 
8.6.3 Cell fixation and Intracellular Ab staining 
In order to stain intracellular antigens, after the surface staining, GBM cells were fixed and 
permeabilized using Cytofix/Cytoperm

 Fixation/Permeabilization Solution Kit (Cat nº: 
554714, BD Biosciences, Trondheim, Norway), through incubation for 20min at 4°C 
protected from light with 200µl of Cytofix followed by a washing procedure (centrifugation, 
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900rpm/10 min) with Cytoperm buffer. The washing was followed by the incubation with 
intracellular Fl-conjugated secondary Ab under the same conditions as with the primary Abs 
incubations.  
 
8.7 Antibodies 
8.7.1 Antibodies for phenotyping assays 
8.7.1.1 NK and PBMC cells 
Various commercially available primary Abs conjugated to different fluorochromes and the 
anti-human Fl-conjugated secondary Abs as well as isotype control Ab were chosen for our 
NK, PBMC and GBM cells staining and flow cytometry phenotyping. These are named in the 
following tables. 
Table 6: Antibodies for flow cytometry phenotyping assays of NK and PBMC cells 
Anti-X 
antibody 
Fluorochrome 
conjugated to 
Stock 
concentration 
(µg/ml) 
Dilution Source 
species 
and clone 
Catalogue 
 number 
Supplier 
CD56 Violet450      
(V450) 
- 1:20 IgG1, 
clone 
B159 
560360 BD Biosciences 
(Trondheim, 
Norway) 
CD3 Violet500      
(V500) 
- 1:20 IgG1, 
clone 
SP34-2 
560770 BD Biosciences  
CD16 Fluorescein 
isothiocyanate 
(FITC) 
- 1:5 IgG1, 
clone 3G8 
555406 BD Biosciences  
CD8 Tandem 
Phycoerythrin-
Cyanine7          
(PE-Cy7) 
- 1:20 IgG1, 
clone 
RPA-T8 
557746 BD Biosciences  
NKG2D Phycoerythrin    
(PE) 
25 1:10 IgG1, 
clone 
149810 
FAB139P R&D Systems 
(UK) 
NKp46 Allophycocyanin 
(APC) 
10 1:5 IgG2b, 
clone 
195314 
FAB1850A R&D Systems 
 
NKG2A Alexa700
®
  100 1:20 IgG2a, 
clone 
131411 
FAB1059N R&D Systems 
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KIR2DL4  APC 25 1:10 IgG2a, 
clone 
181703 
FAB2238A R&D Systems 
 
KIR2DL1 Alexa700
®
 20 1:100 IgG1, 
clone 
143211 
FAB1844N R&D Systems 
 
KIR2DL3  APC 25 1:10 IgG2a, 
clone 
181701 
FAB2014A R&D Systems 
 
KIR2DS4 - 500 1:25 IgG2a, 
clone 
179315 
MAB1847 R&D Systems 
CD4 BrillViol570
®
 - 1:20 IgG1, 
clone 
RPA-T4 
300533 BioLegend (Oslo, 
Norway) 
KIR3DL1 Alexa700
®
 500 1:20 IgG1, 
clone 
DX9 
312712 BioLegend 
KIR3DL1/2 PE 100 1:10 IgG1, 
clone 
5133 
130-095-
205 
Miltenyi Biotec 
(Scheelavägen, 
Sweden) 
KIR2DL2/3 PE 100 1:10 IgG2a, 
clone 
DX27 
130-092-
618 
Miltenyi Biotec 
CD14 Tandem 
Phycoerythrin-
Cyanine647          
(PE-Cy647) 
- 1:20 IgG1, 
MEM-15 
21279147 ImmunoTools 
(Friesoythe, 
Germany) 
KIR2DS2  - 960 1:800 IgG, clone ab101524 Abcam (UK) 
(-) In stock concentration column represents that the information was not provided by the supplier. 
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Table 7: Primary antibodies for flow cytometry phenotyping assays of GBM cells 
Anti-X 
antibody 
Fluorochrome 
conjugated to 
Stock 
concentration 
(µg/ml) 
Dilution Source 
species and 
clone 
Catalogue 
 number 
Supplier 
nestin Phencyclidine-
Cyanine5.5 
tandem     
(PCP-Cy5.5) 
- 1:20 IgG1, clone 
25/NESTIN 
561231 BD Biosciences 
(Trondheim, 
Norway) 
CD15 PE-Cy7 - 1:20 IgM, clone 
HI98 
560827 BD Biosciences  
HLA-ABC APC - 1:5 IgG1, clone 
G46-2,6 
562006 BD Biosciences  
vimentin PE - 1:20 IgG1, clone 
RV202 
562337 BD Biosciences  
HLA-
DR,DP,DQ 
FITC - 1:5 IgG2a, clone 
Tu39 
562008 BD Biosciences  
MICB APC 10 1:40 IgG2b, clone 
236511 
FAB1599A R&D Systems 
(UK) 
MICA AlexaFluor488 100 1:40 IgG2B, clone 
159227 
FAB1300G R&D Systems 
 
ULBP-1  - 25 1:10 IgG2a, clone 
170818 
MAB1380 R&D Systems 
 
ULBP-2/5/6 - 25 1:10 IgG2a, clone 
166510 
MAB1298 R&D Systems 
 
ULBP-3 - 25 1:10 IgG2a, clone 
166510 
MAB1517 R&D Systems 
 
A2B5 PE 100 1:10 IgM, clone 
105-HB29 
130-093-
581 
Miltenyi Biotec 
(Scheelavägen, 
Sweden) 
CD133 APC 50 1:10 IgG1, clone 
AC133 
130-090-
826 
Miltenyi Biotec 
GFAP  FITC 500 1:25 IgG1, clone 
GA5 
53-9892 eBioscience 
(Ireland, UK) 
HLA-E PE 100 1:20 IgG1, clone 
3D12HLA-E 
12-9953 eBioscience 
CD31 PE-Cy7 12 1:20 IgG1, WM-
59 
25-0319 eBioscience 
HLA-G PE 50 1:20 IgG2a, clone 
87G 
12-9957 eBioscience 
(-) In stock concentration column represents that the information was not provided by the supplier. 
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Table 8: Isotype antibodies for flow cytometry phenotyping assays 
Isotype 
antibody 
type 
Fluorochrome 
conjugated to 
Stock 
concentration 
(µg/ml) 
Dilution Source 
species and 
clone 
Catalogue 
 number 
Supplier 
IgG1 V450 100 1:20 clone MOPC-
21 
560373 BD Biosciences 
(Trondheim, 
Norway) 
IgM PE-Cy7
®
 200 1:20 clone G155-
228 
560856 BD Biosciences 
IgG2a  Alexa700
®
 50 1:20 clone 20102 IC003N R&D Systems 
(UK) 
IgG1 PE - 1:20 clone  
PPV-06 
21275514 ImmunoTools 
(Friesoythe, 
Germany) 
IgG2b FITC - 1:20 clone 
PLRV219 
21275533 ImmunoTools 
IgG2a FITC - 1:20 clone PPV-04 21275523 ImmunoTools 
(-) In stock concentration column represents that the information was not provided by the supplier. 
Table 9: Secondary antibodies for flow cytometry assays 
Anti-X antibody Fluorochrome 
conjugated to 
Stock 
concentration 
(µg/ml) 
Dilution Catalogue 
number 
Supplier 
Fragment of goat 
anti-mouse IgG 
PacOrange 2000 1:40 P31585 Invitrogen 
(Hämeenlinna, 
Finland). 
Goat polyclonal 
anti-rabbit IgG 
AlexaFluor647
®
 2000 1:100 Ab150079 Abcam (UK) 
 
Table 10: Antibodies for flow cytometry NK cells cytotoxicity assays with blocking antibodies 
Anti-X antibody Stock 
concentration 
(µg/ml) 
Dilution Source 
species and 
clone 
Catalogue  
number 
Supplier 
KIR2DS4 500 1:25 IgG2a, 
clone 
179315 
MAB1847 R&D Systems 
(UK) 
NKG2D 500 1:25 IgG1, clone 
149810 
MAB139 R&D Systems 
KIR2DS2  960 1:800 IgG, clone Ab101524 Abcam (UK) 
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Table 11: Isotype antibodies for flow cytometry NK cells cytotoxicity assays with blocking antibodies 
Isotype 
Antibody  
type 
Stock 
concentration 
(µg/ml) 
Dilution Source species 
and clone 
Catalogue  
number 
Supplier 
IgG2a 500 1:25 clone 20102 MAB003 R&D Systems 
(UK) 
IgG1 500 1:25 clone 11711 MAB002 R&D Systems 
IgG 500 1:4000 Rabbit, clone Ab37415 Abcam (UK) 
 
 
8.8 Cytotoxicity assays 
8.8.1 Cytotoxicity assays of LAK cells and NK cells against GBM target cells 
In order to investigate the ability of LAK cells and NK cells from each donor to kill different 
patient-derived GBM cells, cytotoxicity assays were performed. LAK cells and NK cells were 
the effector cells while GBMs were the target cells for the killing.  
Cytotoxicity assay consists of co-culturing both effector and target cells in different ratios to 
identify the dose efficacy. Effector: target ratios in the range between 1:2 to 1:30 were 
performed depending on the amount of cells available from each donor and patient-derived 
GBM for the experiment. In order to detect and normalize for the values of spontaneously 
dead target cells without any effect from the effector cells, negative control sample was 
included. The negative control tubes consisted of monoculture of 1x10
4
 target cells. 
Furthermore, three replicates of each condition of study were performed to optimize and 
obtain statistical variation of the data. 
To be able to distinguish the target from the effector cells, target cells were labelled with 5(6)-
Carboxyfluorescein Diacetate N-succinimidyl ester (CFSE, Cat nº: 21888-25MG-F, Sigma-
Aldrich), which is an intracellular fluorescent dye. The staining procedure was 1ml of 5mM 
CFSE per 2x10
6
 target cells and they were incubated during 20min at 37°C protected from 
light and briefly mixed every 5 min. Once they were stained they were resuspended as 
1x10
4
cells/100µl RPMI-1640-Glutamax complete medium and added to the corresponding 
tubes (see Table 11, columns). 
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The effector cells were also resuspended in 100µl of the same medium in different 
concentrations depending on the effector ratios required for each condition (Table 11, rows). 
The cells were cultured in a final volume of 200µl of the complete medium for 4h at 37°C and 
5% of CO2 in FACS tubes. 
Table 12: An example of a diagram of cytotoxicity assay performing. 
 
Each individual square inside the big square delimited by bold black line represents one sample. All the 
samples contained 1x10
4 
of the corresponding target cells depending on the column they were in and 
20x10
4
, 10x10
4
, 50x10
4
, 2x10
4 
or 0 effector cells depending on the row. It is illustrated how 3 replicas of 
each condition were performed. 
After 4h of incubation and the washing procedure (centrifugation 900rpm/10min), the 
samples were stained, 1 min before being acquired by the cytometer, with 1µl of 1mM TO-
PRO3
®
-3 iodide in DMSO (TO-PRO, Cat nº: T3605, Invitrogen) in order to detect the dead 
cells. TO-PRO is a blue DNA intercalating dye that, due to the disruption of the membrane of 
the dead cells, is able to penetrate to the nuclei and stain their DNA.  
Finally, the data was acquired on the BD LSR Fortessa cytometer (BD Biosciences) and 
analysed with use of BD FACSDiva software (BD Biosciences). With the data from BD 
FACSDiva some calculation were carried out by Microsoft Excel (Windows) to get the 
cytotoxicity effect of each donor’s effector cells. 
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Where: 
% lysis: % of target cells killed by the effector cells.  
D: number of dead target cells under co-culture conditions with the effector cells (Figure 16, 
B). 
SD: number of dead target cells under monoculture of target cells conditions (Figure 16, A). 
8.8.2 Cytotoxicity of NK cells with blocking antibodies  
In order to mechanistically prove the involvement of the KIR2DS2 and KIR2DS4 activating 
receptors we found to be relevant in NK cytotoxicity, we performed cytotoxicity assays 
against patient-derived GBM cells (n=2) using donors’ (n=4) NK cells with or without 
blocked activating receptors.  
These cytotoxicity assays with blocking antibodies were performed in the same way as the 
simple cytotoxicity assays but with addition of blocking Abs. Cytotoxicity assays with single 
blocking of NKG2D, KIR2DS2 or KIR2DS4 receptors were performed as well as double and 
triple blockings. No blocking Ab and Isotype control Abs conditions were used as controls to 
ensure that the results were due to a specific blocking. Target: Effector ratios in the range 
between 1:5 and 1:20 were performed and three replicates of each condition of study were 
performed to obtain statistical significance of the data. NKG2D, KIR2DS2 or KIR2DS4 
receptors were phenotyped in order to determine their expression level in each donor. 
 
8.9 Flow cytometry 
Flow cytometry is a biophysical technique used for analysing different parameters of 
individual cells in heterogeneous samples. A flow cytometer is required for these 
measurements, and in this study a BD LSRFortessa
®
 cytometer (BD Biosciences) was used.  
Flow cytometer is a machine that accomplishes the measurements by passing the cells in a 
soluble sample one by one through a laser beam. The signal emitted by the cells is processed 
by the different parts of the system, detected by the different detectors and treated and 
% lysis = (D-SD)*100 
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analysed statistically by the software, in this case BD FACSDiva
®
 Software 6.0 (BD 
Biosciences) [94, 95]. 
Importantly, flow cytometer utilizes 3 types of detectors (Figure 12) depending on the 
processing of the signal it receives: 
 Forward Scatter (FSC) detector: Detects the light scattered forward by the cell while 
passing through the laser beam. It provides data proportional to the cell size.  
 Side Scatter (SSC) detector: Detects the light dispersed in all the directions by the 
granules that cells have in the cytosol. It provides values proportional to the 
complexity/granularity of the cells. 
 Fluorescence detectors/channels: Each channel detects the specific wavelength of the 
fluorescence emitted by the sample after passing through a serial of mirrors and filters.  
Figure 12: Diagram of a Flow cytometer. 
 
Figure taken from [96]. 
8.9.1 Phenotyping assays 
8.9.1.1 Frame setting 
Since the main purpose of employing flow cytometry was to determine the expression of 
multiple markers/antigens of the cells in multiple samples, multi-parametric flow cytometry 
assays were performed. Thus, well-defined frames of the different Fl-conjugated Ab used in 
each sample-tube were required. As the different filters of the cytometer detect the emission 
A 
B 
C 
D 
E 
G F 
A) Laser beam 
B) Fluidic System 
C) FSC detector. 
D) SSC detector.  
E) Fluorescence detectors  
F) Mirrors system 
G) Optical Filter system 
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light within different wavelengths, Fl-conjugated Abs used in the same tube needed to have 
separate emission spectra and to be detected by different detectors.  
Despite making correct choices within the Fl-conjugated Ab repertoire, in multi-parametric 
flow cytometry assays spectral overlapping is inevitable. Spectra overlap is the detection of 
various emission spectra by one filter or the sharing of emission spectra area by different 
Fluorochromes. The spectral overlap can be corrected by compensation (The compensation 
procedure is explained in detail in chapter 8.9.1.3). 
8.9.1.2 Machine setting 
It is very important to properly set-up the cytometer in order to get satisfactory data from the 
samples. For the acquisition, it is crucial to set the voltages of the emitted fluorescence signals 
within the correct range of fluorescence intensity in order to avoid signal loss and obtain 
optimal data. Therefore, compensation tubes (containing cells stained with single Fl-
conjugated Abs or dyes) are used to adjust the voltage settings (Figure 13).  
Figure 13: Histograms of the machine setting procedure. 
 
(A) The signal obtained has too high voltage. (B) Correct voltage for the signal –no signal is lost. (C) The 
signal obtained has too low voltage.  
8.9.1.3 Compensation 
Before starting with the analyses, it is necessary to compensate the signals obtained from the 
different channels. This means to correct the spectral overlap by excluding the signal caused 
by the neighbouring fluorochromes. 
For the compensation, single Fl-conjugated Ab stained samples are required. From the data of 
the compensation tubes, the signal detected by the other filters that are not the corresponding 
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one for the specific Fl-conjugated Ab is subtracted from these filters (Figure 14). This 
subtracted signal occurs because of the broadness of the emission peak of the Fl-conjugated 
Ab that overlaps with other filters with closer wavelength detection.  
Figure 14: Compensation procedure example on BD Horizon V450 channel against BD Horizon V500 
channel. 
 
(A) Non-compensated signal. (B) Well-compensated signal. (C) Over-compensated signal. 
8.9.1.4 Analyses 
In order to remove the background and debris that could interfere with data and give false 
florescence signals, a proper gating of the data is required. Therefore, there are four dot plots 
and gating procedures that are required before starting the analysing: 
1. FSC/SSC (Figure 15, A) is required in order to gate the cell populations in the sample 
based on correct size and avoid the debris –corresponding to the very small 
fragmented particles. 
2. FSC/Time (Figure 15, B) was used to remove the data acquired when the cytometer 
was not appropriately set-up –corresponding to white bands without plotted cells 
(Figure 15, B, arrows).  
3. SSC-A/SSC-H (Figure 15, C) was needed to include only data from single cells and to 
avoid the doublets and clumps of cells that may give false fluorescence percentages.  
4. FSC/Live Dead stain (Figure 15, D) was used to ensure that the data analysed was 
from live cells –dead cells may give auto-fluorescence for certain wavelength 
detectors and bind Abs unspecifically. 
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Figure 15: Dot plots and gating procedures required before analysing of phenotyping data. 
 
(A) FSC/SSC: To gate the cells of interest -lymphocytes. (B) FSC/Time: Data acquired correctly gated. 
The arrows correspond to data acquired when cytometer was not appropriately set-up (C) SSC-A/SSC-H: 
The gate corresponds to single cells. (D) FSC/Live Dead stain: live cells (Live Dead
-
) are gated. 
8.9.2 Cytotoxicity assays 
8.9.2.1 Machine setting 
As it is for the cellular phenotyping, it was very important to properly calibrate the cytometer 
in order to obtain accurate data from the samples. Therefore, the voltage settings were 
adjusted to obtain optimal signal. 
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However, in the cytotoxicity assays, it is not needed to use compensation control samples 
(with single dye) because there is no significant spectral overlap between signals emitted by 
the dyes used in the assay.  
8.9.2.2 Analyses  
Similar to the phenotyping assays, dot plots and gating are required before starting the 
analysis, but in this case, only FSC/SSC (Figure 16, A), FSC/Time (Figure 16, B) and SSC-
A/SSC-H (Figure 16, C) are required. FSC/Live Dead was not used as a “cleaning” procedure 
as previously in the phenotyping assays because the cell death was a parameter that was a 
variable and expected result of our experiments. Cell death was thus recorded as data. 
For the cytotoxicity assays, TO-PRO3, that has an excitation of maximum 642nm 
wavelength, was used as a death indicator, while CFSE with a 521 nm maximum excitation 
wavelength was used to distinguish effector and target cells in the plot. The wide difference in 
the maximum excitation wavelength makes them suitable to be used together in flow 
cytometry detection. APC and FITC channels were used in order to detect the death and 
target-stained signals, respectively, from the samples (Figure 16). 
Figure 16: Dot plots and gating required for analysing cytotoxicity assays. 
 
(A) FITC/APC dot plot of a monoculture of target cells sample. (Aa) Live target cells. (Ab) SD: Dead 
target cells. (B) FITC/APC dot plot of a co-culture sample. (Ba) Live target cells.  (Bb) D: Dead target 
cells. (Bc) Live effector cells. (Bd) Dead effector cells. 
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8.10 DNA isolation and Genotyping  
The GBM and NK cell DNA extraction and genotyping procedures explained below were 
carried out with the assistance of colleagues in the research group and ProImmune LTD 
Company, respectively.  The data from these experiments were required to obtain mechanistic 
insights into the differential cytotoxicity findings of the project. 
8.10.1 DNA isolation 
To obtain DNA for the genotyping, the DNeasy Blood and Tissue Kit (Qiagen, Germantown, 
MD, USA) was used to isolate DNA from 1x10
6
 GBM cells and 200µl of whole donors’ 
blood. The first step of the isolation was different for GBM and blood sample. In the case of 
the blood, this was mixed with proteinase K, PBS and RNase A incubating for 2min, while 
GBM cells needed to be centrifuged for 5min at 300g, to take out the supernatant, and then 
they were resuspended with PBS and proteinase K overnight. RNase A was added the day 
after and incubated for 2min. Thereafter, the procedure was the same for both samples but the 
amounts were added in a 2 fold for the blood sample (according with the manufacturer’s 
protocol). Lysis buffer was added and incubated for 10min at 56ºC. Afterwards pure ethanol 
was added and the sample was placed in the DNeasy Mini Spin column to proceed to 
centrifuge the samples 4 times in a row. The first, second and fourth centrifugations were for 
1min at 8000rpm while the third one was at 14000rpm for 3min, all 4 at room temperature 
and in all the centrifugations but the last one, the flow-through was discarded. Before the 
second centrifugation ethanol based wash buffer was added, ethanol based wash buffer of 
higher concentration was added before the third and before the last one elution buffer was 
added and incubated for 1min to get the DNA out of the column. The last centrifugation was 
repeated to get as much of sample as possible. 
Myself, Justyna Kmiecik and Mateusz Zelkowski isolated the DNA from the samples for 
these experiments. 
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8.10.2 Genotyping 
8.10.2.1 GBM Human Leukocyte Antigen (HLA) genotyping by PCR-SSOPs 
The 2µg DNA at concentration 20µg/ml from GBM cells was sent to ProImmune LTD 
(Oxford, UK) who performed sequence specific oligonucleotide probes polymerase chain 
reaction (PCR-SSOPs) in order to determine the presence of HLA ligands. 
PCR-SSOP is a PCR based method that consists of the use of sequence specific 
oligonucleotide probes (OP) conjugated to fluorescent microspheres that bind to the different 
HLA genes. PCR is thereafter performed to amplify the PCR gene products. The resulting 
sample from the PCR amplification is then incubated with a panel of OP, which binds the 
genes of interest, if this is the case. Therefore the presence of the genes is detected by 
Luminex
®
 as fluorescent signals from the OP bound to the paired DNA sequences.   
8.10.2.2 Donors’ KIR receptors genotyping by PCR-SSPs 
The DNA from Donors’ blood was genotyped for killer immunoglobulin like receptors (KIR) 
genes by a KIR-typing Kit (Miltenyi Biotech, Gladbach, Germany) that is a Sequence-specific 
primer Polymerase Chain Reaction (PCR-SSPs) based Kit. Justyna Kmiecik and Mateusz 
Zelkowski carried out this procedure and I assisted in the data interpretation.  
PCR-SSPs is a PCR based method that consists of the use of DNA primers for specific 
sequences of the region of interest. This is a very accurate procedure that can discern single-
nucleotide polymorphisms. In our case the primers were specific, non-overlapping sequences 
of the 15 different human KIR receptor known genes and 2 pseudogenes (KIR2DS4del, with 
a deletion, and KIR2DS4ins, with an insertion). The presence of the gene of interest is 
detected as PCR amplification product by electrophoresis on an agarose gel.     
The PCR was performed in a MJ Research PTC-200 Peltier Thermal Cycler by using 2-3µg 
(25µl of 75-125µg/l) of donors’ DNA per each sample with a buffer containing Taq DNA-
Polymerase. The samples established for the PCR are: (1) 17 samples for the different KIRs 
typing containing a positive internal control primer which leads a 400bp band in each sample; 
(2) 1 sample with the 100bp DNA ladder (500µl/ml, New England BioLabs, Ipswich, 
England) to define the sizes; (3) 1 positive control for the PCR with the positive internal 
control primer, will only leads the 400bp band; and (4) negative control with no DNA. The 
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amplification by PCR consisted in a single cycle at 95ºC for 60s. and 28 cycles of 94ºC for 
20s., 63ºC for 20s. and 72ºC for 90s. After the cycling, the samples were disposed in a 2% 
agarose gel (Nusieve
®
 3:1 Agarose, Lonza) containing Ethidium Bromide (EtBr, 10mg/ml in 
H2O, Sigma-Aldrich), 1µl per 25ml of gel, to be run in an electrophoresis for 40min. at 100V 
in a BioRad with Horitzontal Gel Elecrophoresis System (Horitzon
®
58, Life Technologies). 
After the electrophoresis, the gel needs to be developed in an UV light chamber with camera 
(Fujifilm) to detect the fluorescence from the intercalated EtBr in the DNA.    
8.11 Statistics 
When comparing more than two variables and categories, we used One-Way Analysis of 
Variance (ANOVA) (with Bonferonni posthoc test). When comparing two groups with one 
variable, two-tailed, unpaired T-tests were performed. In all analyses probability values less 
or equal to 0.05 were considered significant.  Descriptive statistics are reported as mean ± 
standard error of the mean (SEM). All statistical analyses were performed with the Prism 
statistical software, version 5.0 (GraphPad, La Jolla, CA, USA). 
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9. Results 
9.1 NK and LAK cells’ biological characteristics in culture. 
PBMC and NK cells were propagated in culture after isolation in order to activate and expand 
their numbers. PBMCs were cultured in RPMI complete medium for 7 days while NK cells 
were maintained in SC supplemented medium for 14 days. As a result, PBMCs became 
lymphokine activated killer cells (LAKs) [51]. Moreover, these LAK cells (Figure 17, Ab and 
Ac) were revealed on flow cytometric forward and side scatter dot plots as heterogeneous 
populations by their size and granularity (Figure 17, Aa). The LAK cells did not proliferate in 
culture and subsequently became reduced in number during the culturing period of 1 week 
(Figure 17, Ad). In contrast, purified NK cells attained activated phenotypes compared to 
their resting states. NK cells (defined as CD3
-
CD56
+ 
large
 
lymphocytes, Figure 17, Ba) 
changed their shape from a rounded phase bright morphology under steady state (Figure 17, 
Bc), to a ramified phase dark morphology after the culturing (Figure 17, Bd). Donor-
dependent variability was observed. NK cells remained viable and were expandable to 6-9 
fold (Figure 17, Be).  
Figure 17: LAK and NK cells biological characteristics in culture. 
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(A) LAK cells. (Aa) LAK cells represented in a FSC/SSC dot plot. (Ab) LAK cells after isolation (0 days in 
culture). (Ac) Phase contrast images of LAK cells after 7 days in culture. (Ad) Line graph shows the 
proliferation of LAK cells from each donor over the course of 7 days in culture. (B) NK cells. (Ba) NK 
cells in a CD56/CD3 dot plot. (Bb) NK cells represented in a forward and side scatter dot plot. (Bc) NK 
cells after isolation (0 days in culture) showing rounded phase bright cells. (Bd) NK cells showing phase 
dark, ramified morphology after 14 days in culture. (Be) Line graph shows the exponential proliferation 
of purified NK cells from each donor during 14 days in culture. Magnification 200X, scale bars represent 
100µm. 
 
9.2 Subpopulations of LAK cells. 
We hypothesized that LAK cells were constituted of heterogeneous cell subtypes. Thus, 
samples of LAK cells from each donor were phenotyped by flow cytometry in order to 
identify these subpopulations. All the donors’ LAK cells were predominantly composed of T 
cells (defined as CD14
-
CD3
+
, Figure 18, A), of which both CTL (CD8
+
CD3+) and Th 
(CD4
+
CD3+) were present (Figure 18, C), and NK cells (CD14
-
CD3
-
CD56
+
, Figure 18, B). 
LAK cells’ major subpopulation was T cells with 72±12,5% of cells (Figure 18, D; 
47,44±11,9% of those were CTL and 28±13% were Th). In addition, LAK cells contained a 
minor NK cell population (18,1±6,4% of all cells, Figure 18, D) that was predominantly 
CD56
bright
CD16
dim
. 
Figure 18: LAK cells subpopulations. 
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(A) T cells population. Dot plot shows T cells gated as CD3
+
CD14
-
. (B) NK cells population. Dot plot shows 
NK cells gated as CD3
-
CD56
+
. (C) T cells subpopulations. Dot plot shows CTL gated as CD8
+
 and Th as 
CD4
+
. (A, B, C) Data represents data represents mean±SEM, n=7. (D) Graph shows percentages of T and 
NK cells in the LAK cells of each donor. ** Two-tailed T-test p= 0.002, n=7. 
  
 
9.3 NK cells’ major subpopulation changed after culture 
In order to investigate the effect of culture on NK cell differentiation, flow cytometry based 
phenotyping analyses of NK cell samples from each donor, before and after being in culture, 
(resting and activated NK cells, respectively) were performed. We aimed to identify the NK 
cell subpopulations, receptor expression and their maturation status. Under steady states, NK 
cells can be divided into four subpopulations based on their expression of CD56 and CD16 
receptors: CD56
bright
CD16
-
, CD56
bright
CD16
+ 
(Figure 19, Ab), CD56
dim
CD16
-
 and 
CD56
dim
CD16
+
 (Figure 19, Aa) [53, 54].  
The major subpopulation of resting NK cells was CD56
dim
CD16
+
 (86,7±6,1%, Two-way 
ANOVA T20.26, df=6 p=0.00001; Figure 19, Aa, Bd) while after activation in culture the 
major subpopulation turned out to be CD56
bright
CD16
+
 NK cells (71±12,62%, Two-way 
ANOVA, T15.77, df=6; p=0.00001; Figure 19, Ab, Bc). There was no significant change in the 
CD56
dim
CD16
- 
NK subpopulations based on culture conditions (Two-way ANOVA with 
Bonferroni posthoc multiple comparisons test, T0.732, df=6; p>0.05; Figure 19, Ba) but after 
activation in culture, the CD56
bright
CD16
- 
NK cell subpopulations were significantly enriched 
(Two-way ANOVA, T5.83, df=6; p=0.00001; Figure 19, Bb).  
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Figure 19: Major subpopulations of resting and activated NK cells. 
 
(A) Dot plot shows CD56 versus CD16 expression of resting NK cells. The major subpopulation in resting 
NK cells is gated: CD56
dim
CD16
+
. (B) Dot plot shows CD56 versus CD16 expression of activated NK cells. 
Activated NK cells’ major subpopulation is gated: CD56brightCD16+. (Ba) Percentages of CD56dimCD16- 
subpopulations in the NK cells of each donor before and after being in culture. (Bb) Percentages of 
CD56
bright
CD16
-
 subpopulations in the NK cells of each donor before and after being in culture. (Bc) 
Percentages of CD56
bright
CD16
+
 subpopulations in the NK cells of each donor before and after culture. 
(Bd) Percentages of CD56
dim
CD16
+
 subpopulations in the NK cells of each donor before and after being in 
culture. Two-Way ANOVA with Bonferroni multiple comparisons Test, n=7. Data represent mean ±SEM. 
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9.4 Dynamic modulation of activating and inhibitory NK cell receptors expression upon 
culture  
 
9.4.1 Activating and cytotoxic receptors 
To investigate whether the differing major subpopulations from resting and activated NK cells 
were associated with prevalence of activating or inhibitory receptors expressed on the surface, 
flow cytometry phenotyping analyses were performed. All the receptors showed a donor-
dependent variability at steady states and dynamic expression in response to the culture 
conditions.  
The expression of NKG2D and NKp46 in resting and activated states showed donor-
dependent variability. Generally NKG2D was highly expressed in both, resting and activated 
states. Interestingly, donors 3, 4, 5 and 7 with fewer NK cells expressing activating NKG2D 
receptors during the resting or activated states, up-regulated NKp46 natural cytotoxicity 
receptors. For example, D3 had fewer NK cells that expressed NKG2D (48,2%) compared to 
62,1% that expressed NKp46 in the resting state (Figure 20, A) NKG2D was up-regulated 
(98,1%) for this donor while NKp46 was radically down-regulated (1,3%) in the activated NK 
cells (Figure 20, B) compared to resting states. In contrast, 97% of D5 resting NK cells 
expressed NKG2D while 50,5% expressed NKp46 (Figure 20, A). The number of NK cells 
expressing NKG2D was down-regulated (78%) for D5 while those expressing NKp46 were 
up-regulated to 71,1% after culture (Figure 20, B). These results might indicate that the 
expression of activating NKG2D receptor equilibrates to the expression of other cytotoxicity 
receptors, such as NKp46.  
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Figure 20: Resting and activated NK cells activating receptors expression (% of cells). 
             
                           
(A) Bar graph shows resting NK cells activating receptors expression of each donor. The asterisk (*) 
points that NKp46 was not phenotyped for resting NK cells from D1. (B) Bar graph shows activated NK 
cells activating receptors expression of each donor. (C) Comparison of inhibitory (before culture) and 
activated (after culture) NK cell expression of NKG2D, NKp46 and NKG2A. 
 
The expression of NKG2D and NKp46 in the major subpopulations of both resting and 
activated states showed donor-dependent variability. Major subpopulations of both resting 
and activated NK cells had mostly high number of cells expressing NKG2D. NKp46 
expression in the major subpopulations of both resting and activated states did not showed 
any clear tendency (Figure 21).  
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Figure 21: Resting and activated NK cells major subpopulations activating receptors expression (% of 
cells). 
 
(A) Bar graph shows NKG2D expression of the major subpopulations of resting and activated NK cells, 
CD56
dim
CD16
+
 and CD56
bright
CD16
+
, respectively, of each donor. (B) Bar graph shows NKp46 expression 
of the major subpopulation of resting and activated NK cells of each donor. The asterisk (*) points that 
NKp46 was not phenotyped for resting NK cells from D1. 
9.4.2 Inhibitory receptors 
The expression of NKG2A inhibitory receptor by resting NK cells was greater than 65% of 
cells expressing it in 4 out of 7 donors while it was less than 31% in the other 3 donors. For 
D4, D6, D7 and D8 it was 77,3%; 90,5%; 93,4% and 69% respectively, while it was 16,3%; 
30,5% and 23,7% for D2, D3 and D5, respectively (Figure 22, A). Upon activation, 6 out of 7 
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donors down-regulated it and only NK cells from D3 up-regulated NKG2A to 52,7% after 
culture (Figure 22, B). Taken together, there was no significant difference (p>0.05) in the % 
cells expressing these receptors before and after culture (Figure 20, C).  
We investigated the expression of the inhibitory KIR receptors on resting compared to 
activated NK cells, (Figure 22, A and B). As expected, donor-dependent variability in the 
expression of the inhibitory KIR receptors was observed. However, in the majority of donors, 
less than 50% of their NK cells expressed KIR receptors on the surface, with the exception of 
D2, where 94,6% and 95,2%, of resting NK cells expressed KIR2DL2/3 and KIR3DL2/1, 
respectively, and 56,1% of D6’s resting NK cells expressed KIR2DL1 (Figure 22, A). In 
addition, expression of KIR2DL4 was negligible in all donors’ regardless of their activation 
status (Figure 22, B).  
The expression of inhibitory KIR receptors was modulated in different ways depending on the 
donor and activation status. For example resting NK cells (Figure 22, A) from D2 expressing 
inhibitory KIR receptors were: 8,7 % KIR3DL1, 0,6% KIR2DL3, 19,1% KIR2DL1, 95,2% 
KIR3DL2 and 94,6% KIR2DL2 while activated NK cells (Figure 22, B) down-regulated 
KIR3DL1 (4,2%), KIR2DL1 (10,9%), KIR3DL2/1 (28,4%) and KIR2DL2/3 (16,5%) and up-
regulated KIR2DL3 (2,6%). On the other hand, in D3 the percentage of resting NK cells 
(Figure 22, Ab) expressing each of the KIRs were 26,6% KIR3DL1, 21,3% KIR2DL3, 19,7% 
KIR2DL1, 47,4% KIR3DL2/1 and 41,2% KIR2DL2/3 while activated NK cells (Figure 22, 
Bb) down-regulated KIR2DL3 expression to 5,8% and up-regulated KIR2DL4 (4,1%), 
KIR3DL1 (32,8%), KIR2DL1 (24%), KIR3DL2/1 (72,5%) and KIR2DL2/3 (38%).  
Taken together, there was no significant difference (p>0.05) in the expression of the KIR 
receptors comparing resting and activated NK cells (Figure 22, C). 
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Figure 22: Resting and activated NK cells inhibitory receptors expression (% of cells). 
 
(A) Bar graph shows inhibitory receptors expression on resting NK cells of each donor. (B) Bar graph 
shows inhibitory receptors expression on activating NK cells of each donor. (C) Comparison of inhibitory 
KIR receptors average expression in resting and activated NK cells. 
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9.5 LAK cells receptors expression 
Next we investigated the impact of culture on receptor expression within the LAK cell 
subpopulations and aimed to determine if similar receptors were expressed as in the purified 
cells. There was a donor-dependent variability in the expression of receptors and in response 
to the culture conditions.  
9.5.1 Receptors expression 
Interestingly, within the LAK cells from donors 2, 4, 5, 6 and 7, the CTL subpopulations up-
regulated NKG2D after being in culture (Figure 23, Aa and Ba), while the NK cell 
subpopulations highly expressed it regardless of culture conditions, with the exception of D2 
that moderately down-regulated NKG2D after culture (Figure 23, Ab and Bb).  
Importantly, the NKp46 natural cytotoxicity receptor was expressed in the major number of 
NK cells than CTL. All the donors’ NK populations expressed NKp46, where 4 out of 7 
donors had more than 60% of cells expressing it after being in culture (Figure 23, Bb) while 
all 7 donors’ CTL populations had less than 10% of CTL expressing it after culture. Six out of 
those 7 donors’ CTL had less than 3% of cells expressing NKp46 (Figure 23, Ba) with no 
difference between the expression in both resting and activate state.  
The expression of NKG2A inhibitory receptor was similar in the CTL and NK cell 
components of LAK cells, both before and after culture. CTL cells from donors D2, D3, D5 
and D6 had 4,2%, 9,5%, 8,8% and 14,9% of cells expressing NKG2A, respectively (Figure 
23, Aa), while NK cells from corresponding donors expressing it were 13,8%, 20,3%, 11% 
and 12%, respectively, (Figure 23, Ab), before culture. D4 and D7 did not express NKG2A 
before culture for any of both populations. However, all the donors’ CTLs highly up-regulate 
NKG2A expression, being 30,1%; 58,3%; 96,9%; 65,8%; 49,7% and 68,8% from D2 to D7, 
respectively (Figure 23, Ba), while 4 out of 6 donors’ NK cells up-regulate it and the other 2 
down-regulate it. NK cells expressing NKG2A after culture were 70,7%; 95,9%; 16,4% 
72,5% of cells from D3, D4, D5 and D7, respectively, which up-regulated its expression and 
11,6% of D2 and 10,4% of D6, that down-regulate NKG2A expression (Figure 23, Bb).  
Collectively, the only receptor that was significantly differentially expressed between the NK 
cell and CTL subgroups of LAK cells was NKp46 (Two-Way ANOVA, T3.82, df=1; p=0.001, 
Figure 23, C). This is consistent with this receptor being a distinguishing marker for NK cells. 
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Figure 23: LAK cells’ CTL and NK cells receptors expression. 
 
(A) Graphs of expressions before culture. (Aa) Bar graph shows expression of NKG2D, NKp46 and 
NKG2A on CTLs of each donor before culture. (Ab) Bar graph shows expression of NKG2D, NKp46 and 
NKG2A on NK cells of each donor before culture. (B) Graphs of expressions after culture. (Ba) Bar graph 
shows expression of NKG2D, NKp46 and NKG2A on CTLs of each donor after culture. (Bb) Bar graph 
shows expression of NKG2D, NKp46 and NKG2A on NK cells of each donor after culture.  (C) Bar graph 
shows a comparison of the average of the number of CTL and NK cells expressing each receptor after 
culture from all the donors.  
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9.5.1.1 KIR receptors expression 
We hypothesised that the CTL and NK cellular subgroups within the LAK cells might 
differentially express the killer immunoglobulin-like receptors (KIRs). Thus, we investigated 
their expression. 
Interestingly, most of the KIR receptors examined were not highly expressed. Both CTLs and 
NK cells in some donors expressed KIR2DL4, KIR3DL1 KIR2DL3, KIR2DL1, KIR2DL2/1 
and KIR2DL2/3, albeit in reduced percentage of cells (between 3,5% and 29%). The 
percentages of cells expressing those KIRs were mostly higher in NK than in CTL cells. 
Hence, as examples D3 expressed KIR3DL1 in 14,1% of CTLs and 28,5% of NK cells and 
D4 expressed KIR3DL2/1 in 4,4% of CTLs and 27,5% of NK cells (Figure 24, A and B).  
Despite this low percentage of cells expressing KIRs, some KIR receptors in donors 3, 4 and 
7 were expressed by more than 50% of cells and with differences between CTL and NK cells. 
D3 had 82,1% of CTLs and 80,3% of NK cells expressing KIR3DL2/1, D4 had 50,3% and 
82% of CTLs and 65,2% and 79% of NK cells expressing KIR3DL1 and KIR2DL1 
respectively, and D7 had 84,7% of CTLs and 84,9% of NK cells expressing KIR2DL1 
(Figure 24, A and B).  
Although the % of NK and CTLs cellular subgroups within the LAK cells that expressed 
KIRs varied in the individual donors, there were no significant differences between these cell 
types, p>0.05 (Figure 24, C). This is consistent with the fact that these are germline-encoded 
receptors. 
Taken together, KIRs expression within LAKs was donor dependent and no significant 
difference was found when comparing LAK subpopulations. However KIR3DL1, KIR3DL2 
and KIR2DL1 were the only KIRs expressed by a large number of cells in some of the 
donors. 
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Figure 24: LAK cells’ CTL and NK cells inhibitory KIR receptors expression.  
 
(A) Bar graph shows CTL inhibitory KIR receptors expression after culture of PBMCs of each donor. (B) 
Bar graph shows NK cells inhibitory KIR receptors expression after culture of PBMCs of each donor. (C) 
Bar graph shows a comparison of the average of the number of CTL and NK cells expressing each KIR 
receptor from all the donors’ LAK cells.   
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9.6 GBM cells markers and ligands expression 
To functionally investigate the cytotoxic efficacy of LAK cells compared to purified NK 
cells, we established GBM primary cultures from patient GBM biopsies obtained from 
surgical resections at Haukeland University Hospital. Several studies have demonstrated that 
GBM cells propagated in serum free stem cell medium as “stem-like” cells are more 
susceptible to NK cell lysis compared to those cultured under serum containing conditions.  
Stem cell-like cells are characterised by expression of markers of immature cell types. 
Therefore, to verify that our primary GBM cultures fulfilled the criteria for stem-like cells, we 
phenotyped them for various markers of immature cell types.  
This stem-like expression was verified with the phenotyping of the stem-like markers 
expression in standard cell lines (U87 and U373) propagated in serum containing medium 
(Appendix I, Table 14). 
9.6.1 CNS cell differentiation markers  
Glial fibrillary acidic protein (GFAP), nestin and vimentin are intermediate filaments (IF) 
expressed at various differentiation states of neural stem cells (NSC). They can be co-
expressed in a cell and their expression has been reported in GBMs [23-27]. 
As expected, we confirmed high expression of nestin, vimentin and GFAP in all the patient 
derived-GBM we used (Figure 25 and Appendix I, table 14). However, fewer 2012-018 
gliosarcoma cells expressed GFAP (21,8%, Figure 25 and Appendix I, Table 14). 89,6±4,96% 
of cells expressed nestin, 90,28±9,63% of cells expressed vimentin and 91,9±5,36% of cells 
expressed GFAP (2012-018 gliosarcoma cells expressing GFAP is not included in this 
average).  
A2B5 is an antibody that recognises several GT3 gangliosides, expressed in early 
differentiation state of GSC (Glioma stem cells). A2B5 antigens were expressed by 39,1% of 
P3 cells, 69,1% of 2010-20-I cells and 9,6% of 2012-018 cells (Figure 25 and Appendix I, 
Table 14). None of the cell lines but 2012-018 (6,8% of cells) expressed CD133, a surface 
glycoprotein expressed on NSC and a marker for cancer stem cells (Figure 25 and Appendix 
I, Table 14). CD15 is a glycoprotein, which enriched expression has been reported in GBM 
[29]. None of the GBMs expressed it significantly, P3 and 2010-20-I did not expressed it at 
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all while 3,8% of cells of 2010-062 and 4,9% of 2012-018 expressed it (Figure 25 and 
Appendix I, Table 14). 
As negative control, we stained the GBM cells for irrelevant marker for endothelial cells and 
immune cells CD31 [97]. As expected none of the cells expressed it significantly, CD31 was 
expressed by only 1,8% of 2012-018 GBM cells consistent with the fact that gliosarcoma 
component has vascular origin [10] (Figure 25 and Appendix I, Table 14).    
Figure 25: Different GBMs’ CNS cell differentiation markers expression.  
 
FITC: Fluorescein isothiocyanate, PE: Phycoerythrin, PCPCy5.5: Phencyclidine-Cyanine5.5 tandem 
fluorochrome  
(A) Bar graph shows the percentage of cells of the different GBMs expressing each CNS cell 
differentiation marker. CD31 is an epithelial marker used as a control. (B) Histograms show expression of 
the 3 intermediated filaments in P3, as an example of positive expression gating. Light grey represents the 
signal of the negative control for this GBM cell line in each channel of detection while dark grey 
represents its signal obtained after staining. (Ba) Signal obtained for P3 stained with anti-GFAP-FITC. 
(Bb) Signal obtained for P3 stained with anti-vimentin-PE. (Bc) Signal obtained for P3 stained with anti-
nestin-PCPCy5.5. 
9.6.2 GBM expression of ligands for NK cells receptors  
Since NK cell cytotoxicity against cancer cells is mediated via the overall balance of 
activating versus inhibitory signals transmitted via ligation of the receptors on NK cells to 
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their cognate ligands on the target cancer cells, we aimed to establish the expression levels of 
the various ligands for NK cell receptors by the GBM cells.  
Human leukocyte antigen A, -B, and -C (HLA-A,B,C) that are ligands for the inhibitory KIR 
receptors were expressed by the majority of GBM cell lines with 89,98±8,09% of the cells 
expressed these ligands in 4 out of 5 cell lines, while the other cell line, 2010-20-I, had 50,3% 
of GBM cells expressing HLA A,B,C (Figure 26 and Appendix I, Table 14).  
While 4 out of 5 cell lines did not express any of the HLA class II molecules, 58,3% of 2012-
018 cells expressed HLA-DR-DP-DQ, ligand for the TCR of Th cells (Figure 26 and 
Appendix I, Table 14). None of the GBM cell lines expressed the non-classical class I HLA-G 
that is the ligand for KIR2DL4 and only 6,4% and 1,7% of 2012-018 and 2010-062 cells, 
respectively, expressed HLA-E, ligand for CD94/NKG2A inhibitory receptor (Figure 26 and 
Appendix I, Table 14).  
MIC-A, MIC-B, ULBP-1, ULBP-2,5,6 and ULBP-3 that are known ligands for the activating 
receptor NKG2D were expressed in very small proportion of cells, with only one exception, 
2010-062, where 65,4% of the GBM cells expressed MIC-A (Figure 26 and Appendix I, 
Table 14). MIC-A was also expressed by very few cells of P3 and 2010-20-I, 2,5 and 3,2%, 
respectively. MIC-B was expressed by only 6,4 and 1,4% of cells of 2012-018 and 2010-20-I, 
respectively, while only 1,2 and 2,9% of 2010-062 GBM cells expressed, respectively, 
ULBP-2,5,6 and ULBP-3 NKG2D ligands (Figure 26 and Appendix I, Table 14).  
Figure 26: Different GBMs’ ligands expression. 
 
HLA: Human Leukocyte Antigen, MICA/B: MHC class-I-chain-related protein A/B, ULBP: UL16 
binding protein. 
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Bar graph shows the percentage of cells expressing each ligand for the NK cell receptor in the different 
GBM cells.  
 
9.7 Cytotoxicity assays 
Since adoptive cellular immunotherapy preclinical and clinical trials for GBM has 
predominantly administered LAK cells [98], we hypothesised that NK cells might be more 
potent effectors against GBM. Thus, we investigated the cytotoxicity efficacy of LAK cells 
compared to NK cells against patient-derived GBM cells in vitro. We also aimed to determine 
the cytotoxic efficacy of resting NK cells compared with activated NK cells. Thus 
cytotoxicity assays using LAK cells, resting or activated NK from the same donor in a cohort 
of (n=8) donors against GBM cells (n=5) were performed. P3, 2010-046, 2010-062, 2010-20-I 
and 2012-018 GBM cell lines were used for this purpose (Table 4 in 8.4.4 section). 
Cytotoxicity assays with the same effector cells were performed against U87 and U373 cells 
grown in serum containing medium (Appendix II, Figure 35). 
9.7.1 Resting NK cells cytotoxic effect 
We hypothesised that NK cells required to be activated to have an efficient cytolytic effect 
against cancer cells. Therefore, we performed cytotoxicity assays of resting NK cells against 
the GBMs and K562. 
While purified resting NK cells exhibited donor-dependent cytotoxicity against the control 
cell line, K562, and 2010-20-I GBM cells (Figure 27, A and C, respectively), none of the 
donors’ NK cells efficiently killed P3 and 2012-018 cell lines (Figure 27, B and D, 
respectively). Importantly, only D4 and D7 derived NK cells demonstrated moderate 
cytotoxicity effect against both control (Figure 27, A) and 2010-20-I (Figure 27, C) cell lines 
and D5 also demonstrated moderate cytotoxicity effect only against the control cell line 
(Figure 27, A). These experiments confirmed our hypothesis showing low or none cytolytic 
effectiveness of resting NK cells against GBM.   
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Figure 27: In vitro cytotoxicity effect of resting NK cells from different donors against GBM cells.   
 
(A) Resting NK cells cytotoxicity effect against K562. (B) Resting NK cells cytotoxicity effect against P3. 
(C) Resting NK cells cytotoxicity effect against 2010-20-I. (D) Resting NK cells cytotoxicity effect against 
2012-018.  
9.7.2 Activated NK cells cytotoxic effect 
After demonstrating that resting NK cells are not an effective cytolytic tool against GBM, we 
to further investigates the hypothesis that NK cells required to be activated to effectively kill 
cancer cell. Thus, cytotoxicity assays of activated NK cells against the GBMs and K562 cells 
were executed. We also hypothesised that GBM cells lacking ligands for the inhibitory KIRs 
present in the donor (inhibitory KIR receptor-HLA ligand mismatch) or presenting ligands 
for the activating donors (activating KIR receptor-HLA ligand match) would be killed more 
efficiently by the NK cells of that donor. To investigate whether the KIR receptor-HLA 
ligand match/mismatch mediate NK cells’ cytotoxic potency against GBM, we examined KIR 
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receptor and HLA ligand genotype and established tables with the mismatch relation between 
all the donors with the different patient-derived GBM we used.  
9.7.2.1 NK cells cytotoxicity against K562 
K562 is a chronic myelogenous leukaemia (CML) cell line with a Philadelphia chromosome, 
no presence of EBV and herpes-like virus and lack of HLA expression [90]. Since HLA are 
the major ligands responsible for the inhibitory signalling of NK cells and K562 cells lack 
them, NK cells easily kill K562 cells. Therefore K562 cells have been established as a 
positive control for the NK cells cytotoxicity. With the same purpose, cytotoxicity assays of 
activated NK cells derived from all the donors against K562 cells were performed.  
All the donors’ activated NK cells exhibited donor-dependent cytotoxic efficacy against 
K562, where all the effectors lysed greater than 60% of the CML cells at E:T ratios over 5 
with the exception of D5’s activated NK cells which lysed 40% of K562 cells (Figure 28). 
Donors’ D3, D4 and D8 activated NK cells were the most cytotoxic against K562 control cell 
line with 80% lysed cells (Figure 28). The high cytotoxic effect that the donors showed 
indicates that all the donors had the ability of being cytotoxic. 
  
Figure 28: In vitro cytotoxicity effect of activated NK cells from different donors against K562 cells.  
 
  
Results 
 68 
 
9.7.2.2 NK cells cytotoxicity against P3 
We observed that activated NK cells from D2, D3, D5, D6, D7 and D8 effectively lysed 35-
55% P3 GBM cells at E:T ratios under 10 (Figure 29, B), with the exception of activated NK 
cells from D1 and D4, that were the least cytotoxic (between 15 and 20% lysis at E:T ratio 5, 
Figure 29, B). In addition, D2 and D5 NK cells had intermediate cytotoxicity of 
approximately 35% lysis at E:T ratio 5 (Figure 29, B). 
To study the hypothesis of the KIR receptor-HLA ligand mismatch as mediator of the NK 
cells’ cytotoxic potency against GBM, KIR-HLA mismatch pattern was correlated to the 
cytotoxicity results (Figure 29, A and B). No correlation between inhibitory KIR-HLA ligand 
mismatch and cytotoxicity efficacy was observed.  
All the donors had mismatch for KIR3DL2 and KIR2DL4 where the P3 GBM cells lacked 
their cognate ligands A3/A11 and HLA-G, respectively (Table 29, A). Out of the donors that 
had greater cytotoxicity against P3 (Figure 29, B), which are D3, D6 and D7, only D3 did not 
have additional mismatch patterns besides those already named above (Table 29, A). D6 
lacked KIR2DL5 and D7 lacked KIR2DL1, KIR2DL3 and KIR2DL5 (Table 29, A). Despite 
those differences in the inhibitory mismatch in these 3 donors, some similarities were found 
in terms of activating KIR receptor matches. All 3 highly cytotoxic donors had KIR2DS4 and 
KIR2DS2 but lacked of KIR2DS1 and KIR2DS5. D3’s effectors had KIR2DS3 genes in 
addition (Figure 29, A). Interestingly, D2 and D5, that exhibited intermediate cytotoxic 
efficacy, showed presence of KIR2DS4 and lack of KIR2DS2 and KIR2DL2 genes. D1’s and 
D4’s effectors that had lowest cytotoxicity, also lacked KIR2DS2 and KIR2DL2 but showed 
presence of KIR2DS1 genes. D4’s effectors also had KIR2DS3 in the genome (Figure 29, A). 
On the other hand D8, which had match in all the KIR receptors with known ligands and 
presented also the genes for KIR2DS1, KIR2DS4, KIR2DS2 and KIR2DS3, had also lowest 
cytotoxicity (Figure 29, A and B). 
Taken together, we concluded that an important role of the activating receptors KIR2DS2 and 
KIR2DS4 might determine potency of activated NK cells against P3 GBM. Although the 
ligands for KIR2DS2 are unknown to the moment, 3 out of 4 donors that have its genes had 
higher cytotoxicity, what may indicate that P3 probably express the cognate ligand for that 
KIR. 
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Figure 29: In vitro cytotoxicity effect of activated NK cells against P3 cells and KIR receptors and cognate 
HLA ligands genotyping table. 
 
KIR: killer immunoglobulin-like receptor; HLA: Human Leukocyte Antigen 
(A) KIR-HLA genotyping mismatch of each donor with P3.     Red represents match (presence of both 
KIR gene on the effector cells and cognate HLA ligand gene on the tumour cells),     green represents 
mismatch (lack of KIR gene on effector cells and/or HLA ligand gene on the tumour cells) and     white 
represents unknown match/mismatch. Only HLA ligands present in the GBMs of this study are 
represented in the tables. (
-
) Superscript in HLA ligands indicates lack of gene for that particular ligand in 
the GBM. (B) In vitro cytotoxicity effect of activated NK cells from different donors against P3 cells.   
9.7.2.3 NK cells cytotoxicity against 2010-20-I 
To test the hypothesis that KIR2DS2 and KIR2DS4 determine the cytotoxic potency of NK 
cells against other GBM cells, we investigated the association of these activating receptors 
with NK cytotoxic potency against 2010-20-I GBM cells. Only activated NK cells from 
donors D3, D4 and D7 were efficient against the 2010-20-I GBM cells, with 60% cell lysis at 
E:T ratio 10 (Figure 30, B). D5 and D6 had very low cytotoxicity (around 10% cell lysis in 
E:T ratios near 10). D1’s effectors were not able to lyse 2010-20-I GBM cells at all (Figure 
30, B).  
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When examining the KIR and their cognate ligand mismatch, no correlation between 
inhibitory receptors’ mismatch pattern and cytotoxicity efficacy was observed. All the donors 
had mismatch for KIR3DL2 and KIR2DL4 genes where the 2010-20-I GBM cells lacked 
their cognate ligands A3/A11 and HLA-G genes, respectively (Figure 30, A).  
D3, D4 and D7’s effectors that had greater cytotoxicity against 2010-20-I, had different 
mismatch patterns, D3 had no mismatch, D4 lacked KIR2DL2 and KIR3DL1, and D7 lacked 
KIR2DL1, KIR2DL3 and KIR2DL5 (Table 30, A). Despite these differences in the inhibitory 
receptor mismatch, similarities were discovered in terms of activating receptor matches. D3 
and D7’s effectors had KIR2DS2 and KIR2DS4 genes but lacked of KIR2DS1 and KIR2DS5, 
while D4’s effectors had KIR2DS1 but lacked KIR2DS2 and KIR2DS4. D3 and D4’s 
effectors also had KIR2DS3 (Table 30, A).  
D5 and D6’s effectors exhibited intermediate cytotoxic efficacy (Table 30, B). D5 had 
KIR2DS1 gene while lacked for the gene of the inhibitory KIR2DL2 and D6 did not have any 
extra inhibitory mismatch but had the genes of the activating KIR2DS2. Both donors also had 
KIR2DS4 genes (Figure 30, A). D1’s effectors had the same inhibitory KIR receptor 
mismatch and activating KIR receptor-HLA ligand matches as D5’s effectors with the 
exception that D1 also lacked KIR2DL5. For D5’s effectors, it was not known the mismatch 
state of KIR2DS5 and KIR3DS1, because their ligands have not been discovered yet, while 
they were lacking in D1 (Figure 30, A).  
To summarize, highly cytotoxic NK cells derived from donors D3 and D7 possess KIR2DS2 
and KIR2DS4 genes. D4’s NK cells that are also highly cytotoxic to 2010-20-I do not have 
KIR2DS2 and KIR2DS4 genes, but have mismatch in inhibitory KIR2DL2 and KIR3DL1, 
where donors D3 and D7 do not have these KIR-HLA mismatches. Donor D4 had also 
additional activating KIR through the presence of KIR2DS1 and KIR2DS3. The potency of 
D3 and D7 may be determined by KIR2DS2 and KIR2DS4 activating KIR-HLA ligand 
matches, whereas activating signals obtained from KIR2DS1, KIR2DS3, KIR2DS5 and 
KIR3DS1 might cause the cytotoxic potency of D4’s NK cells.  
Overall, these data support the dominance of activating signals provided by KIR2DS2 and 
KIR2DS4 in determining cytotoxic potency of activated NK cells against GBM cells, whose 
loss could be compensated for through presence of numerous other activating KIRs.   
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Figure 30: In vitro cytotoxicity effect of activated NK cells against 2010-20-I cells and KIR receptors and 
cognate HLA ligands genotyping table.                                                                           
 
KIR: killer immunoglobulin-like receptor; HLA: Human Leukocyte Antigen 
(A) KIR-HLA genotyping mismatch of each donor with 2010-20-I.    Red represents match (presence of 
both KIR gene on the effector cells and cognate HLA ligand gene on the tumour cells),     green colour 
represents mismatch (lack of KIR gene on effector cells and/or HLA ligand gene on the tumour cells) and    
-  white colour represents unknown match/mismatch. Only HLA ligands present in the GBMs of this 
study are represented in the tables. (
-
) Superscript in HLA ligands indicates lack of gene for of that 
particular ligand in the GBM. (B) In vitro cytotoxicity effect of activated NK cells from different donors 
against 2010-20-I cells.  
9.7.2.4 NK cells cytotoxicity against 2012-018 
To investigate the robustness of the hypothesis that KIR2DS2 and KIR2DS4 determine NK 
cells cytotoxic potency against GBM, we aimed to establish this association for 2012-018 
GBM cells with gliosarcoma differentiation that expressed high levels of HLA-DR,DQ, DP in 
addition to HLA-A,B and C. 
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Activated NK cells from donors D6, D7 and D8 exhibited intermediate cytotoxicity against 
2012-018 gliosarcoma differentiated GBM cells in the range of 20-25% lysis at E:T ratio 10, 
while D5’s and D3’s NK cells were unable to kill the 2012-018 cells (Figure 31, B).  
In terms of inhibitory mismatch, all 5 donors had inhibitory KIR-HLA mismatch for 
KIR2DL4 where the 2012-018 GBM cells lacked their cognate ligand HLA-G (Figure 31, A). 
In addition, D5’s effectors lacked KIR2DL2, D6 and D8 lacked KIR2DL5 and D7 lacked 
KIR2DL1, KIR2DL3 and KIR2DL5 (Figure 31, A). Thus, no association between inhibitory 
mismatch pattern and cytotoxicity efficacy was observed. 
Importantly, when examining the activating KIR receptor-HLA ligand matches, D3, D6, D7 
and D8 derived NK cells may have KIR2DS2 gene while D5’s effectors did not have this and 
all of them had KIR2DS4 gene (Figure 31, A). Moreover, KIR2DS1 gene was present in D3, 
D5 and D8’s effectors while KIR2DS3 was matched in D3 and D8 and was not present in the 
genome of the other donors (Figure 31, A).  
Taken together, the data indicate that KIR2DS2 may contribute to the cytotoxic potency in 
addition to KIR2DS4. 
 
Figure 31: In vitro cytotoxicity effect of activated NK cells against 2012-018 cells and KIR receptors and 
cognate HLA ligands genotyping table. 
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KIR: killer immunoglobulin-like receptor; HLA: Human Leukocyte Antigen 
(A) KIR-HLA genotyping mismatch of each donor with 2012-018.    Red represents match (presence of 
both KIR gene on the effector cells and cognate HLA ligand gene on the tumour cells),    green colour 
represents mismatch (lack of KIR gene on effector cells and/or HLA ligand gene on the tumour cells) and    
-  white colour represents unknown match/mismatch. Only HLA ligands present in the GBMs of this 
study are represented in the tables. (
-
) Superscript in HLA ligands indicates lack of gene for that 
particular ligand in the GBM. (B) In vitro cytotoxicity effect of activated NK cells from different donors 
against 2012-018 cells.  
 
9.7.2.5 NK cells cytotoxicity with blocking antibodies 
To provide experimental proof that KIR2DS2 and KIR2DS4 determine NK cell cytotoxic 
potency, we aimed to functionally block the interaction with their HLA-cognate ligand and 
investigate the effect on their cytotoxic efficacy. NKG2D was also blocked as positive 
control.  
To confirm the presence of those receptors in the NK cells surface, their expression was 
evaluated by flow cytometry phenotyping. NKG2D was highly expressed by all the 4 donors 
(93,58±3,43%, Figure 32, A) while KIR2DS2 and KIR2DS4 were differently expressed by 
the 4 donors. Interestingly, D3 and D8 that had more cells expressing KIR2DS2 (49,5% and 
61,2%, Figure 32, A) than the other donors, did not expressed KIR2DS4. In addition, D6 and 
D7, which expressed KIR2DS2 in less number of cells than the other donors (11,5% and 
18,2%, respectively, Figure 32, A), did also express KIR2DS4, 7,4% and 18% of cells express 
it, respectively.  
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Figure 32: Phenotype profile of the donors used in the NK cells cytotoxicity with blocking antibodies. 
 
PE: Phycoerythrin, PE-Cy7: Phycoerythrin-Cyanine7 tandem fluorochrome, APC: Allophycocyanin 
(A) Bar graph shows the percentage of D3, D5, D6 and D7’s activated NK cells expressing NKG2D, 
KIR2DS2 and KIR2DS4 activating receptors on the surface. (B) Histograms show expression of the 3 
receptors, blocked in the experiment, for donor 8 as an example of positive expression gating. Light grey 
represents the signal of the negative control for this donor in each channel of detection while dark grey 
represents its signal obtained after staining. (Ba) Signal obtained for NK cells stained with anti-KIR2DS4-
PE. (Bb) Signal obtained for NK cells stained with anti-NKG2D-PE-Cy7. (Bc) Signal obtained for NK cells 
stained with anti-KIR2DS2 Ab together with a secondary APC-Ab.  
To prove the importance role of KIR2DS2 and KIR2DS4 receptors, cytotoxicity assays with 
activated NK cells against P3, 2012-018 GBMs and K562 and blocking antibodies were 
performed. Blocking Ab against KIR2DS2, KIR2DS4 and NKG2D, as a control, were used.  
The cytotoxicity effect of NK cells from D7 against P3 diminished at low E:T ratios when 
blocking KIR2DS2 and KIR2DS4 were present (Figure 33, A). When those blocking Ab were 
present together with anti-NKG2D the cytotoxicity potency was highly reduced, also 
compared with NKG2D blocking alone, that had intermediate effect (Figure 33, B). The low 
expression of KIR2DS2 and moderate in KIR2DS4 showed by the phenotyping assays 
(Figure 32, A) may explain the difference observed with both blocking Ab. 
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Cytotoxicity assays against the same cell line were also performed with D8 NK cells as 
effector, in that case no diminution of cytotoxicity was observed when blocking KIR2DS4 
while the results were similar as for D7 when KIR2DS2 was blocked (Figure 33, C). Less 
cytotoxicity was also observed when NKG2D was blocked and/or the blocking Abs were 
combined (Figure 33, D). This different cytotoxicity inhibition observed can also be linked to 
the blocked receptors expression level (Figure 32, A). In addition, as control, cytotoxicity 
experiments were established with isotype controls for the receptors in study and, as expected, 
all presented similar cytotoxicity as the controls (Figure 33, A, B, C and D). However, same 
experiments were performed for D3 and D6 NK cells but the blocking of KIR2DS2 and/or 
KIR2DS4 did not result in abrogation of cytotoxicity (data not shown). 
The same cytotoxicity experiments were performed against 2012-018 due to presenting 
different phenotype. When KIR2DS2 or KIR2DS4 receptors of D6 NK cells were blocked the 
lysis of 2012-018 cells decreased, but less than in the blocking the NKG2D receptor case 
(Figure 33, E). The combination of blocking Ab resulted in additive abrogation, as in the P3 
case (Figure 33, F). However, the cytotoxic decrease with the blocking of KIR2DS2 and 
KIR2DS4 was not as robust as in the case of blocked NKG2D, what might be partially 
explained again with the low and moderate expression levels of KIR2DS2 and KIR2DS4, 
respectively, observed (Figure 32, A).  
In the case of D7 cytotoxicity assays against 2012-018, no diminishing of cytolysis was 
observed when KIR2DS2 was blocked alone (Figure 33, G). However, when KIR2DS2 was 
blocked with NKG2D or in combination of both NKG2D and KIR2DS2, 2012-018 cells were 
less killed (Figure 33, H). Same experiments against 2012-012 were performed with D3 and 
D8, but no effect was observed when blocking for KIR2DS2 and/or KIR2DS4 (data not 
shown). 
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Figure 33: Cytotoxicity assays with blocking antibodies against NKG2D, KIR2DS2 and KIR2DS4. 
 
 
rbIgG: rabbit Immunoglobulin G; mIg: mouse Immunoglobulin 
(A, B) Donor’s 7 activated NK cells cytotoxicity effect against P3 with addition of blocking Ab alone or 
combined or isotype control Ab. (C, D) Donor’s 8 activated NK cells cytotoxicity effect against P3 with 
addition of blocking Ab alone or combined or isotype control Ab. (E, F) Donor’s 6 activated NK cells 
cytotoxicity effect against 2012-018 with addition of blocking Ab alone or combined. (G, H) Donor’s 7 
activated NK cells cytotoxicity effect against 2012-018 with addition of blocking Ab alone or combined. 
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9.7.3 NK cells versus LAK cells cytotoxicity  
Given that LAK cells are predominantly used as effector cells in GBM immunotherapy 
clinical trials [98], we aimed to investigate whether the LAK cells were more cytotoxic 
against GBM cells compared to purified activated NK cells derived from the same donor.  
The NK cell susceptible K562 cell line was killed more efficiently by the NK cells from 
donors D1, D2, D3, D4, D7 and D8 than by LAK cells derived from the same donors (Figure 
34, A, B, C, D, G and H, respectively). Contrary, D5’s LAK cells killed K562 more 
efficiently than its purified NK cells (Figure 34, E) whilst D6’s NK and LAK cells were 
equally cytotoxic against K562 (Figure 34, F).  
D1, D2, D3, D6 and D8 NK cells were more cytotoxic than LAK cells against P3 GBM 
(Figure 34, A, B, C and F, respectively) while D5 showed no difference in cytotoxic efficacy 
between both effector cells (Figure 34, E). Nevertheless, D4 and D7’s LAK cells 
demonstrated to be more efficient than their NK cells against P3 (Figure 34, D and G, 
respectively). Interestingly, when evaluating the cytotoxicity effect against 2010-20-I GBM 
cells, D3, D5, D6 and D7’s NK cells were more efficient than their LAK cells (Figure 34, C, 
E, F and G, respectively) and no donors’ LAK cells exhibited higher cytotoxicity potency 
than corresponding NK cells against 2010-20-I. 
Furthermore, the cytotoxic efficacy against 2012-018 GBM cells was investigated for 2 
donors and both D6 and D7’s LAK cells exhibited better potency than their corresponding 
NK cells (Figure 34, F and G, respectively). In the case of D6’s NK and LAK cells, the 
cytotoxicity levels were similar but for D7 LAK cells were highly potent than NK cells with 
% lysed cells greater than 60% at E:T ratio 10.  
Taken together this shows a tendency of NK cells to be more cytotoxic against the control cell 
line K562, P3 and 2010-20-I GBM cells than LAK cells. Nevertheless, it was not the case 
against 2012-018 were LAK cells were more effective.   
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Figure 34: In vitro cytotoxicity effect of LAK cells and activated NK cells from 7 different donors against 
GBM cells.  
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(A) Donor’s 1 LAK cells and activated NK cells cytotoxicity effect against P3 and K562. (B) Donor’s 2 
LAK cells and activated NK cells cytotoxicity effect against P3, K562 and 2010-20-I. (C) Donor’s 3 LAK 
cells and activated NK cells cytotoxicity effect against P3, K562, 2010-20-I and 2012-018. (D) Donor’s 4 
LAK cells and activated NK cells cytotoxicity effect against P3, K562 and 2010-20-I. (E) Donor’s 5 LAK 
cells and activated NK cells cytotoxicity effect against P3, K562 and 2010-20-I. (F) Donor’s 6 LAK cells 
and activated NK cells cytotoxicity effect against P3, K562, 2010-20-I and 2012-018. (G) Donor’s 7 LAK 
cells and activated NK cells cytotoxicity effect against P3, K562, 2010-20-I and 2012-018. (H) Donor’s 8 
LAK cells and activated NK cells cytotoxicity effect against P3, K562 and 2012-018.    
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10. Discussion 
GBM is the most frequent and aggressive brain tumour where despite multimodal therapies, 
the patients have very poor prognosis of 14,6 months median survival [34]. GBM tumour 
induces anti-inflammatory microenvironment by secretion of immunosuppressive factors and 
expression of inhibitory molecules for the immune response. Therefore, the immune cell 
subpopulations surrounding the tumour are reduced and an immune suppressive 
microenvironment is created [99]. Thus, novel immunotherapies with adoptively transferred 
cells capable of switching the microenvironment to a pro-inflammatory one may contribute to 
re-establishing an immune response against the GBM, resulting ultimately, in its elimination.  
Immunotherapy clinical trials in patients with GBM have been predominantly administered 
using LAK cells generated by culturing PBMCs ex vivo [50, 51, 98]. LAKs are a mixture of 
activated lymphocytes composed of a major population of T cells and a minor population of 
NK cells. Moreover, LAK cells may create a subpopulation of regulatory T cells, which has 
been reported to present inhibitory functions against NK cells [100]. In addiction T cells may 
contribute to potentially fatal Graft versus host disease (GvHD) [101] while NK cells do not 
induce it [102]. Currently, there is several ongoing investigations using purified NK cells as 
immunotherapy effectors against GBM and 6 clinical trials in different phases are registered 
on www.clinicaltrials.gov [98]. Therefore the goal of our study was to investigate the 
cytotoxic efficacy of NK cells against glioblastoma. We hypothesised that NK cells capacity 
to kill GBM stem-like cells may be determined by the KIR-HLA ligand mismatch hypothesis. 
Thus, we compared the cytotoxic potency of purified resting NK cells, activated NK cells and 
LAK cells from the same healthy donor against the GBM stem-like cells.  
 
10.1 NK and LAK cells’ biological characteristics in culture. 
As NK cells comprise only 5-20% of peripheral blood lymphocytes it may be difficult to 
obtain adequate numbers for NK-mediated immunotherapy. Moreover freshly isolated NK 
cells are typically in a resting state and require subsequent activation for efficient target 
engagement. Protocols for their expansion are thus required.  
We demonstrated that NK cells could be expanded 6-9 fold in the presence of IL-2 and 
antibodies to NKp46 and CD2 coupled to microbeads. However, for clinical purposes this 
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technique has two very important weaknesses, (1) 6-9 fold give us a very low number of cells 
not optimal for clinical applications and (2) this is an expanding method by using Miltenyi 
expanding kit, which requires the ligation of NK cells to microbeads to get activated. These 
beads would require to be removed before a clinical treatment, a procedure extremely difficult 
to perform without affecting the viability of the cells. These weaknesses make this method, 
although efficient, not very practical for clinical application. Hence, other well defined 
techniques, such as expansion from umbilical cord blood CD34
+
 cells or co-cultivation with 
irradiated human Jurkat T-lymphoblast line (KL-1) cells (ex vivo expansion of NK with 
irradiated tumour) that has been recently established, would be needed. In the first one, 
Dolstra et al. obtain 1000-fold NK cell expansion with near 100% of purity by a protocol with 
2 consecutive differing culturing conditions of CD34
+
 umbilical cord cells in one month 
[103]. In contrast, Lim et al. co-cultured PBMC cells from blood with irradiated KL-1 cell 
line sensitive for NK cytotoxicity which stimulated the NK cells to expand to 100-fold with 
90% purity in 15 days [104]. Although there were effective expansions, where they obtained 
NK cells expressing different KIRs, activating receptors, such NKG2D, and CD56
bright
 
marker, both techniques had small subsets of CD16
+
 NK cells. Based on our results, it is 
necessary to have higher CD16
+
 NK cell subsets for potent cytotoxicity effect and CD16 
expression would also be useful for inducing ADCC in combination therapies with 
monoclonal antibodies. 
LAK cells could not be expanded efficiently in the presence of IL-2 and IL-15, despite the 
fact that they were cultured following the current protocol that is used for clinical application 
[105]. This feature represents a rate-limiting step for their successful application, as one 
would need to start the culture with a lot of cells from the donors to obtain an adequate 
number of cells for the treatment. Owing to the patients’ often weak general condition, 
autologous transfer of patient own cells at high doses might be difficult to achieve.  
 
10.2 Subpopulations of LAK cells. 
As reported in previous studies that used LAK cells as immunotherapy effectors [50, 51], we 
observed a mixed phenotype of the LAK cells. While NK cells were greater than 96% pure 
after culture, LAK cells consisted of predominantly T-lymphocytes, the majority of which 
were CTLs, followed by Th cells. The NK cell fraction in LAK cells was minor and 
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represented approximately 18% of cells. Interestingly, these NK cell subsets within the LAK 
cells exhibited CD56
bright
CD16
dim 
major phenotype, the cytokine responsive
 
phenotype 
previously reported to be more prone to IFNγ production [106]. This subpopulation of NK 
cells was the same as the one observed in the resting NK cells, which did not have potent 
efficacy of killing GBM cells.  
We showed that LAK cells contain a mixture of T cells and NK cells with a donor dependent 
composition. As an example we obtained much higher proportion of NK cells in D7’ LAK 
cells than the average and greater cytotoxicity of those against 2012-018. Likely, that was due 
to larger NK cell population they had. This donor variability in the composition of LAKs and 
the unpredictability of the therapeutic aspects it may have, might pose challenges to 
standardising LAK-based treatments in clinical trials. However, it has also been reported 
donor variability in LAKs composition in one study with cytotoxicity assays against cells 
infected with Toxoplasma-Gondi [107] but few of the LAK cell studies do phenotype 
characterisation and quantify both NK cells and CTLs subsets from LAKs like we did in the 
present study.  
 
10.3 NK cells’ major subpopulation changed after culture 
As Caligiuri et al. and Zimmer et al. reported, we also obtained a CD56
dim
 CD16
+
 
predominant subpopulation of resting NK cells. After activation in culture, as expected, the 
CD56
bright
CD16
+ 
NK cell subpopulations were significantly enriched and became the major 
subpopulation [53, 54]. This switch upon culturing to a CD56
bright
 is a well-known behaviour 
of the NK cells cultured by IL-2, in addition this phenotypic switch augments NK cells 
cytotoxicity activity [53].  
According to Caligiuri et al. and Zimmer et al. findings, CD56
dim
CD16
+
 NK cells 
(corresponding to our resting NK cells) contain the major number and content of cytolytic 
granules while CD56
bright
CD16
+
 (corresponding to our activated NK cells) are more efficient 
in cytokine production and with higher ADCC efficiency [53, 54]. Our findings validate and 
confirm the studies from these independent laboratories.  
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10.4 NK cells versus LAK cells cytotoxicity 
Since several trials with adoptive cellular immunotherapy against GBM are accomplished by 
LAK cells [98] and the major cytotoxic effectors within the LAK cells might be NK cells 
[107] we hypothesised that NK cells might be more potent effectors against GBM. Thus, we 
studied the cytotoxicity efficacy of LAK cells compared to NK cells against patient-derived 
GBM cells in vitro.  
Although there was a general trend for NK cells being more potent than LAK cells against the 
GBM stem-like cells, there was a donor dependent cytotoxic efficacy for LAK cells against 
GBMs. In our study we compared cytotoxicity potency of LAK cells with a 
CD56
bright
CD16
dim
 NK subset with purified NK cells that were predominantly 
CD56
bright
CD16
+
. Their obvious difference was the expression of CD16 molecules in the 
surface, which confines CD16
+
 higher ADCC efficiency than CD16
dim
 [53, 54], but this 
cytotoxicity function is not relevant in in vitro assays due to the lack of antibodies to 
recognize the Fc portion by CD16. In addition, the distinguishing marker for NK cells, 
NKp46, was significantly expressed by NK cells than CTLs, what reflects the NK cell 
lineage. 
Despite the fact that cytotoxic efficacy of LAK cells is likely a result of both NK and CTLs 
derived mechanisms, Subauste et al. experiments showed better cytotoxicity effects with 
donors’ LAK cells enriched with NK cell subsets [107], tempting one to presume that NK 
cells may be the major mediators of the cytotoxicity within LAK cells populations. We found 
that D7 LAK cells, as an exception, were composed of greater NK cell numbers compared to 
CTLs and they were be more potent against P3 and 2012-018 GBM cells than the other LAK 
cells and even the purified NK cells. 
Taken together, the findings support our hypothesis and indicate that NK cells are a better 
option as immunotherapy effectors against GBM than LAK cells. 
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10.5 Dynamic modulation of activating and inhibitory NK cell receptors expression upon 
culture  
10.5.1 Activating and cytotoxicity receptors 
In our study, there was no significant difference in density levels of NKp46 and NKG2D 
between the resting and activated NK cells. The expression of NKG2D and NKp46 in the 
major subpopulations of both resting and activated states showed donor-dependent variability. 
While major subpopulations of both resting and activated NK cells had mostly high number 
of cells expressing NKG2D, they had, generally, less cells expressing NKp46. However, the 
results suggested that the expression of activating NKG2D receptor equilibrates to the 
expression of other cytotoxicity receptors, such as NKp46. This compensation hypothesis has 
also been established in the case of (1) NKG2D and DNAM-1 in mice [108] by Gilfillan et al. 
and compensation of activating receptors may also be the case in the very recent publication 
of Sheppard et al., where they demonstrated that (2) double mutant mice of NKp46 and 
NKG2D accomplish NKG2D and NKp46 related functions [109]. Hence, since our 
compensation hypothesis between NKG2D and NKp46 has not been described previously, it 
may indeed be a novel funding. However, further studies with larger number of donors are 
required to confirm this tendency. 
10.5.2 Inhibitory receptors 
The expression of NKG2A inhibitory receptor by resting NK cells showed donor-dependent 
variability but most of the donors down-regulated the number of cells expressing NKG2A 
after the culture. Although no evidence of direct NKG2A down-regulation has been reported 
previously, NKG2A
-
/Fas
+
 NK populations were found by Son et al. in new-onset psoriasis 
patients and were defined as an activated pro-inflammatory phenotype [110]. Despite this 
NKG2A down-regulation observation, there was no significant difference (p>0.05) in the % 
cells expressing these receptors before and after culture. Nevertheless, NKG2A did not 
represent a relevant receptor in our study due to none of the tumour cells included in our 
research expressed its ligand, the non-classical HLA-E.  
Donor-dependent variability in the expression of the inhibitory KIR receptors was observed, 
this is consistent with the fact KIR have different haplotypes, with a large variability of genes 
in each one, and allelic polymorphism [71, 72]. However, most of the donors had low number 
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of NK cells (<50%) expressing inhibitory KIRs and their expression was modulated in 
different ways and with no statistical significance depending on the donor and activation 
status.  
 
10.6 LAK cells receptors expression 
LAK cells’ subpopulations receptor expression was investigated in order to determine the 
similarities between LAK cells and purified NK cells that could explain the cytotoxicity. As 
in the case of pure NK cells, donor-dependent variability in the expression of receptors and in 
response to the culture conditions was observed, consistent with the published literature [68]. 
Despite the fact that there were no significant differences in the expression of activating 
NKG2D or NKG2A inhibitory receptors between NK cells and CTLs fractions of the LAK 
cells, NK cells were denoted by elevated NKp46 expression compared to the CTL 
subpopulation. This is consistent with the notion that NKp46 is the most specific marker for 
NK cells across mammalian species [111] although discreet subsets of T cells weakly express 
it. 
Mingari et al. reported in their study that KIRs are also expressed by a small fraction of T 
cells [112]. Indeed, expression of KIR has been described on both CD4 T cells, in the context 
of cytomegalovirus infected cells [113], and on CD8 T cells [114], in which they found 
different expression of the KIRs in CTLs than in NK cells. Therefore we hypothesised that the 
CTL and NK cellular subgroups within the LAK cells might differentially express the KIRs 
and thus impact on their differential cytotoxic potency against GBM. In our experiments, 
KIRs were not-highly expressed in general terms in LAK cells and, surprisingly, no 
significant difference in their expression on CTLs and NK cells was observed in our study.  
 
10.7 GBM cells markers and ligands expression 
We investigated the phenotypic features of the GBM primary cultures we established from 
patient GBM biopsies obtained from surgical resections at Haukeland University Hospital. As 
reported previously, the expression of stem-like markers on GBM cells affects the 
cytotoxicity of NK cells against GBM cells [66, 115]. Therefore, the GBM cell lines were 
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phenotyped for various markers of immature cell types and for the activating and inhibitory 
ligands for NK cell receptors. The same phenotyping was established for the standard cell 
lines U87 and U373 propagated in serum containing medium for comparison (Appendix II, 
Figure 14). 
10.7.1 CNS cell differentiation markers and stemness 
Glial fibrillary acidic protein (GFAP), nestin and vimentin were highly expressed by most of 
the GBMs and it is consistent with previous reports [10, 23, 26]. They are all intermediate 
filaments (IF) expressed at various differentiation states from neuronal stem cells (NSC) and 
can be co-expressed in the same cell to make hetero-filaments that include sometimes 2 of 
those [23-27]. However, only low expression of GFAP was demonstrated in 2012-018 GBM 
cells and this is consistent with the fact that this is a gliosarcoma differentiated GBM. This 
GBM histological type is denoted by both neuroepithelial and mesodermal features consistent 
with its organisation from vessels, hence the name gliosarcoma.  
A2B5 is an antibody that recognises several GT3 gangliosides, while CD133 and CD15 have 
been speculated to identify GSCs by some authors [26, 28, 29]. Despite the fact that the 
cancer stem cell hypothesis has been refuted for glioblastoma, these markers are albeit 
expressed, and may represent the cellular heterogeneity of GBM rather than their stemness or 
states of CSC origins. Our results were consistent with the reports of seldom expression of 
CD133 on the GBM cells. While A2B5 was expressed in cells of 3 out 5 of the GBMs, only 
6,8% of the cells of 2012-018 expressed CD133 and only 3,8% and 4,9% of 2010-062 and 
2012-018 cells, respectively, expressed CD15.  
Other markers of “stemness” such as SOX2, Ki-62 and neuron glial-2 (NG2) have also 
investigated in other studies [66, 115]. Inclusion of these markers would complete our study 
of characterisation of the stemness state of our GBM cultures. However, we unable to 
efficiently optimise the methods of assessing these markers, thus they were not included in 
our results.  
10.7.2 GBM expression of ligands for NK cell receptors  
There have been only two publications in the last 3 years utilizing purified NK cells to target 
glioma cells propagated in vitro as stem-like cells [66, 115]. Castriconi et al. investigated the 
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susceptibility of GBM stem-like cells to resting or IL-2 long-term cultured NK cells. They 
reported that GBM cells expressed levels of HLA class I that were not sufficient to protect 
against NK mediated lysis [66]. However, we also report expression of HLA A,-B,-C in all 
the GBMs and as in Castriconi et al. experience, they might be expressed in a not protective 
density for the NK cytotoxicity.  
Furthermore, Castriconi et al. concluded that the mechanisms were mediated by combined 
action of NK natural cytotoxicity receptors (NCRs) NKp46 and DNAM-1 [66]. DNAM-1, 
together with NKp30 and NKp44, were not included in our phenotyping experiments; 
therefore, we cannot presume their contribution in the NK cell cytotoxicity against the GBM 
cells.  
None of our patient-derived GBM primary cultures expressed the non-classical class I HLA-G 
and only few cells of 2012-018 and 2010-062 GBMs expressed HLA-E, both ligands for 
CD94/NKG2A inhibitory receptor. None of the HLA class II molecules were expressed by 
any of the GBMs, with the exception of 2012-018 GBM that had more than 50% of the cells 
expressing HLA-DR-DP-DQ. As this is a ligand for the TCR of Th cells, this may be the 
reason why 2012-018 cells are killed more efficiently by the LAK cells from some donors 
than by their NK cells.  
NKG2D receptor ligands, MIC-A, MIC-B, ULBP-1, ULBP-2,5,6 and ULBP-3 were not 
highly expressed by any of the GBM cells. 2010-062 cells, that highly expressed MIC-A, 
were an exception, but, unfortunately, no comparable cytotoxicity assay was established with 
this cell line. MIC-A was also expressed by 2,5% of P3 and 3,2% of 2010-20-I cells. MIC-B 
was expressed by 6,4% of 2012-018 cells and 1,4% of 2010-20-I cells. And only 1,2% and 
2,9% of 2010-062 GBM cells expressed ULBP-2,5,6 and ULBP-3, respectively. Despite their 
low levels of expression, they nevertheless contribute to NK cell cytotoxicity since blocking 
of NKG2D abrogates the killing efficacy. However, the low expression of ULBPs is 
consistent with reports from other studies [66].  
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10.8 Cytotoxicity assays 
Since we confirmed that purified NK cells kill efficiently GBMs compared to LAK cells 
generated from the same healthy donor, we aimed to determine the cytotoxic efficacy of 
resting NK cells compared to activated NK cells. 
10.8.1 Resting NK cells cytotoxic effect 
Our results showed a donor-dependent moderate cytotoxic effect of purified resting NK cells 
against K562 CML Leukaemia cell line, consistent with previous reports [66], and against 
2010-20-I GBM, but none had the ability to kill efficiently p3 and 2012-018 GBM cells. 
Based on the results obtained from the genotyping of 2010-20-1 GBM cells, the ability of 
resting NK cells to kill this GBM might have been mediated by reduced inhibitory signals as a 
result of 3 inhibitory KIR-HLA ligand mismatch and increased activation signals. In addition, 
the 2010-20-I cell line had lower expression levels of HLA-A,B,C than the other ones (50,3% 
of cells expressing it compared to 89,98±8,09% of the other GBMs), a fact that may result in 
less interaction with inhibitory KIRs, leading to penetration of more activating signals and 
subsequent cytolysis. 
It has been reported that NK cells in steady states express CD56
dim
, contain more cytolytic 
granules, higher amount of their content and present more cytotoxic activity while CD16
+
 are 
more efficient in ADCC [53, 54]. Due to this fact and as the major subpopulation of resting 
NK was CD56
dim
CD16
+
, higher cytotoxic effect of the resting NK was expected. However, 
the low cytotoxicity efficacy may be because of the fact that under the in vitro conditions, 
ADCC does not happen, as explained above. Furthermore, the fact that CD56
dim
 containing 
more cytolytic granules may not necessarily be related to their efficiency to secrete their 
content. 
10.8.2 Activated NK cells cytotoxic effect. 
10.8.2.1 NK cells cytotoxicity against K562 
Since the cytotoxicity assays against K562 were established as a positive control due to the 
susceptibility of this cell line to the cytotoxicity effect of NK cells [66], high cytotoxicity 
effect was expected. Correspondingly, all our studied donors effectively killed K562 cells. 
Unexpected, however, was the donor-dependent effect, which may be explained because of 
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the donors’ different expression of the other receptors mediating the cytotoxicity against 
K562, such as NKG2D that recognize the stress ligands and NKp46 whose ligands are as yet 
unknown.   
 
10.8.2.2 NK cells cytotoxicity against patient-derived GBMs 
Aware that resting NK cells were not able to kill efficiently GBMs, cytotoxicity assays of 
activated NK cells against GBMs were performed to investigate the hypothesis that activated 
NK cells are more proficient in killing GBMs than resting NK cells and also LAK cells. 
Our cytotoxicity assays suggested that the activating receptors KIR2DS2 and KIR2DS4 might 
determine cytolytic potency of activated NK cells against P3, 2010-20-I and 2012-018 GBMs. 
The donor NK cells with the highest cytotoxicity against P3 had KIR2DS2 and KIR2DS4 
genes while the NK cells from the donors with intermediate cytotoxicity efficacy had only 
one of the activating receptors, KIR2DS2, and lacked KIR2DS4. Finally the two donors with 
the lowest cytotoxic efficiency lacked KIR2DS2 while only one had KIR2DS4 genes. This 
data may also suggest that KIR2DS2 is the most relevant activating KIR of the two, although 
their ligands are at present unknown. Moreover, 2 out of 3 donors with high cytotoxic 
efficient NK cells against 2010-20-I possessed both genes, KIR2DS2 and KIR2DS4, while 
donors with intermediate cytotoxic potency had only KIR2DS4 genes. The other donor with 
high cytotoxic effect, despite not having both KIR2DS2 and KIR2DS4 receptors, may have 
compensated for this lacking with the possession of numerous additional activating receptors.  
Cytotoxicity assays against 2012-018 gliosarcoma was established because this is a GBM 
with gliosarcoma differentiation that expressed high levels of HLA-DR, DQ, DP in addition 
to HLA-A, B and C and which exhibited different mismatch pattern than the other GBMs. 
Importantly, despite all the donors included in the assays against 2012-018 had KIR2DS4 
match and KIR2DS2 gene, there was no high cytotoxicity effect against 2012-018. Most 
likely the high levels of HLA-DR, DQ, DP award protection against efficient killing by NK 
cells. 
10.8.2.3 NK cells cytotoxicity with blocking antibodies 
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To confirm our hypothesis that KIR2DS2 and KIR2DS4 determine NK cell cytotoxic 
potency, we aimed to functionally block their interaction with the HLA-cognate ligand to 
determine whether it affects their cytotoxic efficacy or not. NKG2D was also blocked as 
positive control due to be an activating receptor highly expressed in NK cells, as we showed, 
and has as ligands various stressed molecules [61].  
Activating receptors KIR2DS2 and/or KIR2DS4 showed an important role in determining 
potency of activated NK cells against all GBM cells P3, 2010-20-1 and 2012-018, where 
regardless of the number of inhibitory KIRs mismatched with their cognate HLA ligands, the 
presence of KIR2DS2 and KIR2DS4 was associated with greater NK cytotoxic potency. 
Likewise, reduced NK cytotoxic potency due to the loss of KIR2DS4 could probably be 
compensated by the presence of other activating KIR. Blocking KIR2DS2 and KIR2DS4 
receptors resulted in decreased cytotoxicity of NK cells against both P3 and 2012-018 cells in 
2 of 4 donors, partially confirming our hypothesis. However, those receptors are expressed 
only on a small proportion of cultured NK cells and this might explain why we did not 
observe as robust lysis abrogation as when NKG2D receptor was blocked. Unfortunately, 
ligands for KIR2DS2, KIR2DS5, KIR3DS1 and for KIR3DL3 and KIR2DL5 are presently 
unknown. Thus, the contribution of these receptors to the cytotoxic potency of NK cells 
against GBM cells could not be assessed. Another caveat to this study is the small size of 
tumours analysed. Although we found a dominant effect of KIR2DS2 and KIR2DS4 in 
determining cytotoxic potency against P3 and 2012-018 GBM cells, and that KIR2DS1 
determined low cytotoxic efficiency of NK cells against P3, 2012-018, 2010-20-1, further 
studies with more tumours are required to confirm these findings. 
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11. Conclusion 
 
Upon 14 days of culturing with the presence of IL-2, NKp46 and CD2 mAb conjugated 
beads, NK cells became CD56
bright
CD16
+ 
and were highly cytotoxic against GBM tumour 
cells, while resting NK cells with a CD56
dim
CD16
+ 
phenotype, did not kill GBMs efficiently. 
Furthermore, activated NK cells tended to be more effective against GBM cells than LAK 
cells, that were composed of a mixture of CTL and NK cells. 
Despite the fact that ligands for many of the activating KIRs (such as KIR2DS2, KIR3DL3, 
KIR2DL5) are presently unknown and hamper the fully exploration of the KIR involvement 
of in the cytotoxic potency of NK cells against GBM cells, our study demonstrated an 
important role of the activating receptors KIR2DS2 and/or KIR2DS4 in commanding the 
potency of activated NK cells against P3, 2010-20-1 and 2012-018. The presence of those 
KIRs were associated with higher efficient cytotoxicity, despite inhibitory KIRs mismatches 
were present. In the case of loss of KIR2DS4, the cytotoxicity potency may be compensated 
by the presence of other several activating KIRs. These findings are highly novel and 
KIR2DS2 and KIR2DS4 may represent biomarkers for identifying the donors with the most 
potent NK cells for allogeneic NK cell immunotherapy. 
Purified NK cells were more efficiently expandable compared to LAK cells. 
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12. Future perspectives 
 
The present study has opened a new perspective in the potential of NK cell cytotoxicity 
against solid cancer. Our findings on the important involvement of activated KIRs in the NK 
cell mediated cytotoxicity should be reproduced after inclusion of larger numbers of donors 
and patient-derived GBM cells to consolidate the implication of activating KIRs for the NK 
cell potency. It will be imperative in the future to perform combination treatments in vitro and 
in vivo in animal models, such as blocking other KIR receptors to identify biomarkers for NK 
cell potency against GBM. Combination adjuvant therapies, such as proteasome inhibitor 
bortezomib, and antibodies against gangliosides, NG2, or epidermal growth factor receptors 
that are established tumour antigens that drive malignant progression could be combined with 
potent NK cells for maximal tumour control. 
Furthermore, there currently exist some controversies regarding the identified KIRs ligands 
expressed on target cells, where many are simply unknown. In the future when these 
disparities are resolved there will be greater potential in identifying further receptor- ligand 
interaction that mediate NK cytotoxicity potency. Their investigation and discovery, together 
with the development of specific antibodies for their further study and application in research 
is key to in depth investigation into the complex mechanism of the HLA-ligand mismatch 
hypothesis. 
Our group is currently performing in vivo experiments where P3 tumour spheres have been 
implanted in mouse brains and different HLA-ligand mismatched donors’ NK cells were 
injected as adoptively transferred immunotherapy. Despite the fact that the results have not 
yet been fully analysed, preliminary data indicate that this is a very promising therapeutic 
approach and will provide further information not attainable from in vitro experiments. 
Therefore, similar experiments with other HLA-ligand mismatched donors’ and with the 
combination of adjuvant therapies would also contribute valuable knowledge on the 
therapeutic potential and possible side effects of NK cell based immunotherapy for solid 
tumours. 
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Appendix I 
Table 13: NK cells receptors 
Receptor Activating (+)/ 
Inhibitory (-) 
Ligand/s 
NKG2D + MICA, MICB, 
ULBPs 
NKp46 + Unknown 
CD94/NKG2A - HLA-E 
KIR2DL/KIR3DL - HLA class I 
 KIR2DL1 - HLA-C2 
 KIR2DL2 - HLA-C1,-C2 
 KIR2DL3 - HLA-C1,-C2 
 KIR2DL4 - HLA-G 
 KIR3DL1 - Bw4-HLA-B 
 KIR3DL2 - HLA-A3,-A11 
KIR2DS/KIR3DS + HLA class I 
 KIR2DS1 + HLA-C2 
 KIR2DS2 + Unknown 
 KIR2DS3 + HLA-C 
 KIR2DS4 + HLA-C 
Table representing NK cell receptors name, whether if they have activating (+) or inhibitory (-) function 
and their cognate ligands names (if they are known). Table adapted from [61-63, 68, 71, 74-77]. 
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Table 14: GBM stem-like markers expression 
 P3 2010-20-I 2010-046 2010-062 2012-018 U87 U373 
GFAP 93 98,9 86,6 89,1 21,8 5,1 1,6 
Vimentin 92,3 87 98,8 98 75,3 86,7 39,9 
Nestin 93,3 94,2 82,2 91,2 87,1 93,9 57,25 
CD31 0 0 0 0 1,8 1,3 5,4 
CD15 0 0,1 - 3,8 4,9 5,7 0,6 
CD133 0 0 - - 6,8 0,6 1,7 
A2B5 39,1 69,1 - 0,4 9,6 4,7 9,6 
HLA-A,B,C 82,4 50,3 83,9 94,7 98,9 89,1 85,2 
HLA-G 0,2 0,2 - 0,1 0 7,4 5,2 
HLA-E 0,2 0,1 - 1,7 6,4 0,8 40,8 
HLA-DR-DP-DQ 0 6,7 - 0,6 58,3 0,9 0 
MICA 2,5 3,2 - 65,4 0 0 0 
MICB 0,1 1,4 - 0,1 6,3 7,9 0,6 
ULBP-1 0,1 0,1 0,1 0,5 0,4 0,3 0 
ULBP-2,5,6 0,2 0,4 0,2 1,2 0,5 0,2 0,3 
ULBP-3 0,1 0,4 0,1 2,9 0,6 0,1 0,1 
Table representing the percentage of cells of the different GBMs expressing each CNS cell differentiation 
marker, each ligand for the NK cell receptor and CD31, an epithelial marker used as a control. 
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Appendix II 
Figure 35: In vitro cytotoxicity effect of resting and activated NK cells from different donors against 
standard cell lines U87 and U373. 
 
 
(A) In vitro cytotoxicity effect of resting NK cells from different donors against U87 cells. (B) In vitro 
cytotoxicity effect of activating NK cells from different donors against U87 cells. (C) In vitro cytotoxicity 
effect of resting NK cells from different donors against U373 cells. (D) In vitro cytotoxicity effect of 
activating NK cells from different donors against U373 cells.   
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